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ABSTRACT 
Background Promotion of job opportunities and tourism in African countries has led to an 
increase in expatriates in malaria endemic areas. A paucity of data exist on characteristics 
and numbers of expatriates and long-term travellers being evacuated from sub-Saharan 
Africa for suspected malaria infections diagnosed while still in Africa.  
Methods A retrospective flight record review of a South African fixed-wing air-ambulance 
provider from June 2006 through July 2009 was performed. Adult expatriates and long-term 
travellers with suspected malaria being evacuated from sub-Saharan African countries to 
Johannesburg, South Africa were included. 
Results Suspected malaria was the single most common diagnosis for dispatching air-
ambulances with 81 (11.9%) of the 679 flights. Accuracy of the initial diagnosis, based on 
confirmation of malaria at the receiving facility was 78.4% for blood smears, 92.3% for rapid 
detection tests and 42.8% for clinical signs alone. P. falciparum (alone, or in combination 
with other Plasmodium species) was the most frequently isolated species at both the 
referring (100%) and receiving (88.2%) facilities in cases where the species was 
documented. The suspected malaria patients were predominantly male 69 (84.1%), with a 
mean age of 42.1 ±12.8 years, and were in sub-Saharan Africa for occupational reasons 65 
(79.3%). Angola, the Democratic Republic of Congo and Mozambique were the countries of 
origin in 48 (58.5%) of the suspected malaria flights. Compliance on appropriate malaria 
chemoprophylaxis was documented in two (2.4%) suspected malaria patients. Intubation as 
a marker of severity was required for 15 (18.3%) patients, and one (1.2%) patient died in-
flight. No statistically significant difference (p=0.50) was shown for intubation requirements 
when comparing patients who had utilised malaria chemoprophylaxis with the patients who 
had not utilised chemoprophylaxis.  
Conclusions Patients presented in advanced stages of severe/complicated malaria with 
concurrent poor chemoprophylaxis utilisation and compliance. Appropriate 
chemoprophylaxis did not decrease the severity of presentation (based on intubation 
requirements) and did not guarantee complete malaria protection. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
 
1.1 Malaria. 
 
Malaria is transmitted through exposure to bites of the female Anopheles mosquito. [1] The 
female requires a blood meal (protein), for the development of her eggs which are later laid in 
water. [2] During the blood meal (biting of a human), the mosquito inoculates sporozoites (from 
her saliva) into the human host, which infect the liver cells, where they undergo asexual 
replication and mature into schizonts. Merozoites are released as the schizonts rupture, and 
enter the bloodstream, infecting red blood cells. The merozoites then either go into the 
erythrocytic cycle, maturing again into schizonts (asexual replication) releasing meroizites within 
the red cells, or differentiate into gametocytes (sexual erythrocytic stage). The erythrocytic cycle 
parasites are responsible for the clinical manifestations of malaria. Gametocytes are ingested by 
an Anopheles mosquito (vector) during a blood meal and through a life cycle starting in the 
mosquito’s stomach, make their way to the mosquito’s salivary glands. This leads to a new 
human being infected during a blood meal and perpetuates the malaria life cycle. [1][3] Four 
species of malaria are known: Plasmodium vivax, P. ovale, P. malariae and P. falciparum.[4] P. 
knowlensi is a simian plasmodia usually found in long- and pig-tailed macaques, which has 
been known to cause clinical infections in humans. [4][5]  P. vivax and P. ovale may produce 
dormant liver stage parasites, which may reactivate months to years later. [2] Malaria incubation 
periods range from seven to 30 days, with the shorter period usually seen with P. falciparum. [2]  
 
Malaria infection is placed into two categories, uncomplicated and complicated. Uncomplicated 
malaria commonly presents with a combination of fever, chills, sweating, headache, nausea and 
vomiting, generalised body aches and malaise. Severe (complicated) malaria manifestations 
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may include cerebral malaria (abnormal behaviour, impaired consciousness, seizures or coma), 
haemolysis (anaemia, haemoglobinuria), respiratory failure (pulmonary oedema, acute 
respiratory distress syndrome), thrombocytopenia, acute renal failure, hyperparisitaemia (>5% 
of erythrocytes infected), hypoglycaemia, metabolic acidosis, cardiovascular collapse or shock. 
[2][6] Any pregnant patient or patient under five years should be considered as complicated 
malaria. 
 
The majority of infections in sub-Saharan Africa are caused by the most lethal of the four 
species, P. falciparum, which is also found in Haiti, the Dominican Republic and Papua New 
Guinea. [7] P. vivax is usually found in Central America, India, Bangladesh and Pakistan. P. 
ovale and P. vivax are found mainly in South-East Asia and South America. P. malariae and P. 
ovale are both uncommon. [1][7][8] P. knowlesi is found in South-East Asia and can be 
misidentified as P. malariae. In a retrospective review by Cox-Singh et al., 316 (31%) of the 
1018 stored blood samples and films were found to contain P. knowlesi (as confirmed by the 
polymerase chain reaction test method) as opposed to the initial erroneous diagnosis of P. 
malariae. [5] The blood samples were from Malaysian Borneo and Peninsular Malaysia obtained 
during the period 2001 to 2006. Four of the fatal cases had been incorrectly diagnosed with P. 
malariae hyperparasitaemia. All four cases presented with severe malaria complicated by 
marked hepatorenal dysfunction and resulted in death. [5] 
 
The number of bites by an infectious mosquito per person per unit of time is referred to as the 
entomological inoculation rate (EIR). The EIR is thought to be the most direct measurement of 
transmission intensity. [9] In a meta-analysis (1980 through 2004) of annual P. falciparum (APf) 
EIR’s, thus the number of P. falciparum positive mosquito bites per person per year, across 23 
of the 54 African countries, it was found that more than 55% of annual P. falciparum 
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entomological inoculation rates (APfEIR) were from Kenya, Burkina Faso, Tanzania and 
Gambia. [9][10] 
 
 
1.2 Confirmatory malaria testing modalities. 
 
Empirical clinical diagnosis remains the most common method of malaria diagnosis in many 
sub-Saharan African regions which leads to over-diagnosis with resultant over-treatment due to 
this methods low sensitivity, the overlap of the malaria symptom complex with many other 
tropical diseases and co-infections. [11][12]The two main methods of confirmatory testing for 
malaria is utilisation of a rapid detection test (RDT), or by microscopy.  
 
 
1.2.1 The rapid detection test. 
 
RDTs incorporate immunochromatographic capture procedures, with monoclonal antibodies 
providing the indicator of infection. [11][12][13] The newer simpler tests work by dropping a 
specified amount of fingerpick blood droplets (5-15µL) into a designated area and then adding a 
specified amount of buffer droplets into another designated area. [4][8][14] As the blood migrates 
across a nitrocellulose membrane the parasite antigens are captured by monoclonal antibodies 
prepared against a malaria antigen target, in effect labelling them during the mobile phase. A 
further monoclonal antibody, applied to a strip of nitrocellulose then captures the antigen-
antibody complex producing a visible coloured line in the immobile phase. The preferred target 
antigens are those which are abundant in both the sexual and asexual stages of the parasite.[13] 
Current tests focus on the detection of histidine-rich protein-2 (HRP-2), which is specific to P. 
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falciparum, and parasite-specific lactate dehydrogenase (pLDH) or Plasmodium aldolase 
enzymes from the parasite glycolytic pathway found in all four Plasmodium species. [13]  
P. falciparum may be detected with HRP-2, P. falciparum-specific pLDH isomer. P. vivax may 
be detected with P. vivax-specific pLDH.[4][11] Different isomers of pLDH do exist for each of the 
four Plasmodium species. [13] 
 
Commercially available RDTs are available as two, three or four bands and contain different 
combinations of target antigens to suit local malaria epidemiology. [4][11] Two-band tests target 
HRP-2 and therefore detect P. falciparum only, whereas the three-band tests also detect other 
malaria parasite antigens (P. ovale, P. malariae and P. vivax) by targeting HRP-2 combined with 
either pLDH or aldolase. [14] The three bands have a control line, a line for P. falciparum and a 
third line for detection of antigens such as pan-Plasmodium-specific pLDH or aldolase, which 
are common to all four Plasmodium species. [4][8] The four-band RDT has a fourth line which 
detects P. vivax through a P. vivax-specific pLDH isomer. [4] 
 
Results of RDT results are available within 5 to 20 minutes. A positive result shows a line in the 
control area as well as the P. falciparum and/or mixed area. Should the control line not be 
visible, then the test is invalid. A negative test will only show the control line. Visible lines may 
be rated as strong, medium, weak and faint and this test line intensity variation has been shown 
to correlate with the parasite densities in both aldolase assays as well as the HRP-2 assay. [4][8] 
 
In a meta-analysis by Marx et al., the malaria results of 5747 non-immune returning travellers 
from malaria endemic areas were analysed to determine the accuracy of RDTs for ruling out 
malaria. [14] Studies were included if the RDTs were compared with expert microscopic 
examination or polymerase chain reaction tests. The meta-analysis found that when testing for 
P. falciparum the HRP-2-based tests were more accurate than the pLDH-based tests. P. 
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falciparum sensitivities were 88-99% for HRP-2 and 79-95% for pLDH. P. vivax sensitivities 
were 46-93% for HRP-2/Aldolase-based tests and 62-95% for pLDH-based tests. P. ovale and 
P. malariae showed low and variable sensitivities of 7-80% for HRP-2/aldolase-based tests and 
36-95% for pLDH-based tests. [14] A study by Van der Palen et al. of the stored blood of 452 
returned travellers using two types of RDTs (the two-band SD FK50 Malaria Ag P. falciparum 
test and the three-band SD FK60 Malaria Ag P. falciparum/Pan test) and referencing with 
microscopy, showed 21 false negative RDT results 15/21 with parasite densities <100/µl and no 
false negative readings with parasite densities above 400/µl. [8] Of the 21 false negative results, 
20 were for P. falciparum and a single mixed sample (P. falciparum and P. ovale) gave a false 
negative result.[8] Overall sensitivities were 87.5% for P. vivax, 76.3% for P. ovale and 45.2% for 
P. malariae, although sensitivity  increased to 92.6% and 90.5% for P. vivax and P. ovale 
respectively at parasite densities above 500/µl. Sensitivity for detection of P. falciparum was 
93.5%, increasing to 97.6% and 100% at parasite densities higher than 100/µl and 1000/µl 
respectively.[8] Thus RDTs have limited exclusion power at low P. falciparum parasite densities 
and a lower sensitivity for non-falciparum species, especially P. malariae. [8]  
 
The World Health Organisation (WHO) has recommended a minimal RDT sensitivity standard of 
95% and specificity standard of 95% for P. falciparum densities of 100/µl. [4][11][14] The WHO has 
published a non-exhaustive list rating some of the commercially available RDTs based on the 
RDTs sensitivity. The WHO stipulates that RDTs must be able to detect 100 parasites/µl 
(0.002% parasitaemia) in all Plasmodium species. [13][15] 
 
The air-ambulance service provider reviewed in this study utilises the three-band ICT Malaria 
Combo Cassette Test (marketed as U-Test in South Africa), which detects P. falciparum 
through HRP-2 and all four Plasmodium species through aldolase. Results are available within 
10 minutes and the cassette is stored at 2-30ºC. [15][16] According to the WHO RDT ratings list, 
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this test has a P. falciparum detection score of ≥ 75% at 200 parasites/μl, a false positive rate of 
<10% and an invalid rate of <5%. This test did not meet the WHO minimal standards for 
detection of P. vivax >75% at 200 parasites/μl. [15] 
 
False negative RDT results may be due to insufficient parasites to register a positive result or 
damage to the RDT itself causing reduced sensitivity. [16] False negative RDT results may also 
be due to the RDT not detecting the species of Plasmodium causing the illness, e.g. when a 
patient is infected with non-falciparum species where a HRP-2 based RDT is utilised. [12][13][16] 
Non-immune patients develop symptoms at lower parasite densities, which may result in more 
false negative tests than in semi-immune patients who develop symptoms at higher densities. 
[11][14]  
 
The HRP-2 concentration increases as the parasite develops from the ring stage to the late 
trophozoite. Although it is found predominantly in the asexual stages, it is also found in 
gametocytes. [11] These HRP-2 producing gametocytes (which do not cause clinical illness) may 
persist, resulting in a false positive HRP-2 based RDT for up to 28 days post successful 
treatment. [4][8][11][16] Due to this HRP-2 persistence despite resolution of malaria symptoms and 
apparent parasite clearance from the host, RDTs have limited usefulness in monitoring of the 
therapeutic response. [13] HRP-2 based RDTs have also shown false positive results in patients 
with circulating rheumatoid factor. [11][16] Although pLDH based RDTs are thought to be more 
appropriate in monitoring treatment than the HRP-2 RDTs, it should be noted that pLDH is 
produced by the plasmodial gametocytes and may thus also cause the RDT to remain positive 
despite the absence of asexual parasite forms. [4][8]  
 
Benefits of the RDT is that it does not require refrigeration, although temperature should be 
maintained between 2-30ºCelcius, has a long shelf life of up to 24 months, does not require an 
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energy source and can be utilised following simple instructions. It is ideal for remote areas 
where microscopy is not available, decreasing the dependence on clinical diagnosis alone. [4][8] 
RDTs offer a rapid diagnosis, requires little training and results are available quickly. [13] In 
remote areas, a positive RDT may result in expediting the initiation of appropriate malaria 
treatment and may be life-saving. A negative RDT, in contrast, may delay appropriate treatment 
if the user is not aware of its limitations. [8] 
 
 
1.2.2 Microscopy. 
 
Ideally, where diagnostic laboratories are available, an appropriately trained microscopist will 
prepare thick and thin blood films stained with Giemsa (pH 8.0) and examine a minimum of 200 
(100-400) fields by light microscopy using a 500-times magnification.[4][8][12][13] The thick-blood 
film concentrates the layers of red blood cells (RBC) by a factor of 20-30, enhancing sensitivity, 
and detects low levels of parasitaemia as well as the reappearance of circulating parasites 
during infection recrudescence or relapse. The parasite densities in thick-blood films are 
estimated by counting the number of asexual parasites against 200 white blood cells and 
multiplying the parasites counted by 40. The parasite density is expressed as parasites/µl blood 
[2][8][13]  
 
The thin-blood film emphasizes the morphological identification of the parasite species and thus 
provides greater specificity than the thick-blood film. Parasitaemia in thin-blood films are 
estimated by counting the number of parasitized RBC seen in 10000 RBC and expressing the 
number of parasitized RBC as a percentage. Thus 1.0% parasitaemia is equal to 50000 
parasites/µl of blood assuming that 1µl of blood contains 5 x 106 RBC. [13] Microscopy is the gold 
standard in diagnosing malaria and sensitivity can be excellent with detection of parasite 
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densities as low as 5 parasites/µl (0.0001% parasitaemia). [4][11][14] Experienced microscopists 
are able to identify to the species level in 98% of all parasites seen. [13] The process of 
examining a thick-blood film takes 5-10 minutes when performed by an experienced 
microscopist and 30-45minutes when only thin-blood films are examined to achieve the same 
detection limit as thick films. [12] Microscopy is able to differentiate different species as well as 
quantify parasites and thus monitor response to malaria chemotherapy. [4][11][14]   
 
It should be noted that, although discouraged by the WHO due to its unreliability, semi-
quantitative expression of parasitaemia, expressed as 1+ to 4+, does still occur in Africa. [17] An 
approximate estimate of the percentage parasitaemia from the “+” method is: 1+ (<0.001%); 2+ 
(0.001-0.01%); 3+ (0.01-0.1%) and 4+ (>0.1%) (personal communication with Prof. J. Frean of 
the National Institute of Communicable Diseases – 2011 April 7). The extrapolation of a 
percentage parasitaemia from the “+” method of reporting is based on assumptions about the 
quality, method and thickness of the slide preparation, the average high power field size of the 
microscope, the average red cell count,  as well as the film being interpreted by a good 
microscopist.  
 
False negative microscopy results may occur with parasite densities less than 5-10 parasites/µl, 
or with sequestered parasites as seen in pregnant patients.[4][11] Patients with P. falciparum may 
also have parasites sequestered in the deep capillaries of the spleen, liver or bone marrow 
which may result in insufficient numbers of the parasite in the circulating blood. This may result 
in a false negative result on the blood films. [13] As parasite densities of P. malariae and P. ovale 
are often low, these mixed infections are often missed by microscopy. [11]  
 
False positive microscopy results post successful malaria treatment may be due to observation 
of circulating parasites which are dead and have not yet been cleared by the host. [13] 
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The process of microscopy is time consuming and labour intensive and it requires appropriately 
trained competent microscopists as well as continued training to remain proficient, a microscope 
in good working order and access to consumables (slides, Giemsa), quality control and quality 
assurance. [4][11][12][13] 
 
 
 
1.3 Malaria in Africa. 
 
Worldwide in 2006, 3.3 billion people were at risk of contracting malaria, mainly with P. 
falciparum, with an estimated 247 million cases resulting in 881 000 deaths (mainly in children 
under five years of age). Nearly 80% (212 million) of the cases were in Africa, with 50% of these 
cases presenting in Nigeria, Democratic Republic of Congo (DRC), Ethiopia, Kenya and 
Tanzania. [18] Malaria eradication was made a top health priority by the World Health 
Organization (WHO) in the 1990’s, leading to the launch of the Roll Back Malaria initiative in 
1998, with the aim of developing a sector-wide approach to combating malaria, with a goal to 
halve malaria mortality rates by 2010. [19] Seven of the 45 African WHO countries/areas 
decreased malaria cases and deaths by 50% or more during 2000 to 2006 as a direct result of 
the WHO initiative. [20] As travel to Africa becomes more popular and more expatriates live in 
Africa for occupational reasons one can expect an increase in expatriate and long-term traveller 
malaria cases being diagnosed and requiring evacuation for complications. Malaria endemic 
areas are visited by an estimated 80 to 90 million travellers annually, with an estimated 10000 to 
30000 travellers contracting malaria. [21][22] 
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1.4 Travellers to Africa. 
 
The risk of malaria to travellers to African regions has been extrapolated as a figure per 100000 
travellers to the region: 302/100000 for West Africa, 240/100000 for East Africa, 357/100000 for 
Central Africa, and 46/100 0000 for Southern Africa. [23] Sub-Saharan Africa (excluding South 
Africa) was found to have the greatest relative risk for malaria in returning travellers. [23] The 
above mentioned figures are from a study by Askling et.al. which was based on Swedish 
residents returning from malaria endemic areas during 1997 through 2003 and testing positive 
for malaria in Sweden. During this period a total of 857 residents contracted malaria, 75% from 
sub-Saharan Africa (93% of all P. falciparum cases). [23] A study by Kofoed et al. found that 
malaria was contracted in 158/100000 travellers returning to Denmark after visiting Gambia, and 
714/100000 travellers visiting Ghana. [24] Of interest is that 10% of travellers to Ghana had 
apparently been treated for malaria in Ghana and did not have malaria on return to Denmark. 
These cases were not captured on the data base. [24] A shortcoming in all these statistics is that 
only cases of imported malaria to the specific country are documented as the patients present to 
medical facilities in their home country, and that travellers diagnosed or treated in Africa are not 
registered. [24][25]  
 
 
1.4.1 European travellers 
 
According to the European Network on Imported Infectious Disease Surveillance 
(TropNetEurop), 1659 cases of P. falciparum were imported into the European Union countries 
from 1999 to 2000. European travellers accounted for 52.4% (869) of the cases and immigrants 
accounted for 47.6% (790) of the cases. The reason for travel in the European travellers group 
was tourism (59.6%), visiting relatives/friends (21.6%), business (15.8%) or other reasons (3%). 
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Chemoprophylaxis was not utilised by 60.4% of the European travellers. The mortality rate was 
0.6% (five patients) and the case-fatality rate among European patients with complications was 
9.1%. More than half of European travellers were infected in West Africa. [25]  
 
 
1.4.2 Travellers from the United States of America. 
 
Approximately 27 million U.S. residents travelled to overseas destinations in 2000 [26] resulting 
in 825 imported malaria cases among U.S. residents, as reported to the National Malaria 
Surveillance System (NMSS). Cases diagnosed outside the United States or one of its 
territories (American Samoa; Guam; Northern Mariana Islands and Puerto Rico) were excluded. 
[27][28][29][30] Thus once again cases diagnosed or treated in Africa were omitted. In comparison, 
713 malaria cases among U.S. residents were reported to the NMSS in 2006, with P. falciparum 
being the predominant species and the majority of cases having originated out of Africa. Six 
malaria-related fatalities occurred in the United States in 2006 with four of the six patients not 
having taken any chemoprophylaxis while travelling in malaria endemic areas. [31] During the 
period from 1963 to 2001, Newman et al. found that 123 malaria-related deaths occurred among 
U.S. travellers and 17 among military personnel. [27] P. falciparum caused 92.7% of the deaths, 
and P. vivax 3.3% of the deaths. Africa, notably Kenya and Nigeria, was the source of the 
majority of fatal imported malaria cases. Only seven of the 123 travellers who died were 
compliant on an appropriate chemoprophylaxis regimen. Cerebral malaria occurred in 48% of 
cases, renal failure in 44%, acute respiratory distress syndrome in 32%, anaemia in 21% and 
disseminated intravascular coagulation in 11% of cases. [27] The case fatality rate (1985-2001) 
for U.S. travellers with imported P. falciparum was 1.3%. [28][29]  
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1.4.3 British travellers. 
 
In a study by Phillips-Howard et al. to identify the risk of malaria of British residents travelling 
abroad, 2948 randomly selected British residents completed a passenger survey at passport 
control of international airports in Britain in 1987. A further 1052 case reports of British residents 
with microscopically confirmed malaria infections in 1987 were also reviewed. [32] It was found 
that the annual infection rates extrapolated as a figure per 100000 travellers was: 555/100000 to 
Nigeria; 779/100000 to Ghana;  28/100000 to Gambia; 149/100000 to Kenya; 212/100000 to 
Tanzania; 138/100000 to Zambia and 789/100000 to Malawi. [32] The annual infection rate per 
100000 travellers per African region was found to be 379/100000 for West Africa, 172/100000 
for East Africa and 128/100000 for Central or Southern Africa. Malaria chemoprophylaxis was 
utilised by 77% of British travellers to West Africa, 83% to East Africa and 54% to Central and 
Southern Africa. [32] Although no actual figures were noted for compliance on chemoprophylaxis 
and compliance was merely stated as poor, travellers returning from West Africa had a 2.5 
times higher rate of P. falciparum infection when not compliant on chemoprophylaxis. [32] 
 
 
 
1.5 Chemoprophylaxis compliance in expatriates and long-term travellers. 
 
Expatriates, for the purpose of this study are defined as non-immune individuals who reside for 
a period in a malaria-endemic country other than their original country of citizenship, with the 
purpose of completing an occupational (mainly) assignment, with the intent to return to their 
home country once the assignment period is completed. [33][34][35]The period of exposure to 
country-related hazards is usually longer with expatriates than with other travellers. [33] 
Expatriates who travel to areas with high malaria rates are particularly vulnerable. [36] In a 
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prospective study by Hill for the period June 1989 to May 1991, 784 U.S. resident travellers 
attended the International Traveler’s Medical Service at the University of Connecticut prior to 
departure and agreed to complete a health questionnaire within two weeks of returning to the 
United States of America. [37] Travellers ages ranged from one to 85 years with a mean age of 
44.1 ± SD 17.5 years. The duration of travel was 90 days or less, with 631 (80%) having 
travelled for 30 days or less and a median duration of 19 days (mean 24 ± 16 days). [37] All 
travellers received extensive counselling and written material on, amongst other issues, the 
prevention of malaria. 612 of the 784 travellers were prescribed malaria chemoprophylaxis: 63% 
chloroquine, 18% chloroquine plus proguanil, 17% mefloquine and the remaining 2% other 
unspecified chemoprophylaxis. Of the 608 travellers who completed the chemoprophylaxis 
compliance information on the postcard, 488 (80%) were completely compliant (taking the 
prescribed number of doses before, during and following their trip). Eight of the 612 travellers 
sought medical attention for fever of an unknown cause, with two having had P. falciparum 
malaria documented, four were treated presumptively for suspected malaria, and the remaining 
two were treated presumptively for pharyngitis and otitis media respectively. Of these six 
travellers treated for malaria, the diagnosis was made in Ghana (three), India (one), Kenya 
(one) and Nigeria (one). Five of these six travellers were on appropriate chemoprophylaxis, and 
the remaining traveller who was one of the two travellers with documented P. falciparum, 
purchased but never took the unspecified chemoprophylaxis. One malaria case required 
hospitalisation without mention of chemoprophylaxis utilisation. An additional film positive case 
was documented in a returned traveller increasing the total number of confirmed plus 
presumptive malaria cases to seven. All three documented malaria cases originated out of West 
Africa, without documentation of specific countries, with two travellers having used 
chloroquine/proguanil chemoprophylaxis and the third traveller not having utilised any 
chemoprophylaxis. In this study the incidence of documented malaria was estimated at 3.8/1000 
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travellers, and the incidence of documented plus presumptive malaria was estimated at 
8.9/1000 travellers. [37] 
 
In a study by Chen et al. it was found that long-term travellers, defined as travelling for longer 
than six months, have a higher risk of contracting malaria than short-term travellers. [35] It was 
also found that long-term travellers exhibited poor adherence to chemoprophylaxis regimens 
and underused personal protective measures. Chen et al. showed that most chemoprophylactic 
regimens, even when taken correctly, provided 75-95% protection against malaria and that no 
chemoprophylactic regimen was 100% effective. [38] 
 
With the objective to elucidate the risk for travel-related diseases of European travellers to five 
chosen malaria-endemic tropical areas, Rack et al. proceeded with a questionnaire-based 
observational study of 658 adult German travellers who consulted the travel clinic of the Berlin 
Institute of Tropical Medicine. [39] The tropical areas were grouped into five groups including: 
Kenya/Tanzania; Senegal/Gambia; India/Nepal; Brazil and Thailand. It was found that 201 of 
the 658 subjects had travelled to tropical areas within sub-Saharan Africa with 167 people 
having travelled to Kenya/Tanzania and 34 to Senegal/Gambia during the study period of July 
2003 through June 2004. [39] The mean duration of travel for all 658 travellers was 23.9 ±10.3 
days with a range of 3-62 days. 276 (41.9%) of the 658 travellers took malaria 
chemoprophylaxis as follows: mefloquine 60.5%; atovaquone/proguanil 31.2%; doxycycline 
5.8%; chloroquine/proguanil 1.8% and chloroquine 0.7%. Chemoprophylaxis compliance was 
reported by 268 (97.1%) of the 276 travellers. This unusually high rate of compliance may be 
due to the subset of travellers who visit travel clinics being more aware of potential medical 
problems and being more willing to take precautions to prevent them. [39] 
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1.6 Quality of care and anti-malarial drugs in Africa. 
 
As the incubation period for malaria is seven to 30 days, it is fair to say that malaria 
management and diagnosis within sub-Saharan Africa will mainly be a problem for the long-term 
traveller and expatriate. Short-term travellers  (six days or less) are more likely to present with 
malaria manifestations in their home country as ‘imported malaria’. All travellers (short- and 
long-term) as well as expatriates would require knowledge of malaria manifestations and 
understand the urgency in going to the nearest appropriate facility to be tested. In many 
instances in Africa, this may require several hours over very poor terrain by motor vehicle, or 
even helicopter or light airplane flights as seen with the flooded plains in the Okavango Delta, 
Botswana. [40] Fixed-wing air ambulance evacuations dispatched by this particular air-
ambulance service provider are usually limited to cases with manifestations of complicated 
malaria, or where the local facilities are not able to provide adequate treatment. Although 
evacuations may be internal within that country, the majority are to the nearest centre of medical 
excellence, which may be in Europe and South Africa, or to regional centres in Kenya. [41]  
 
Once the traveller has tested positive for malaria another hurdle is encountered. Access to anti-
malarial treatment in 18 of the 46 WHO African-region countries was on average 38%, and no 
African country reached the WHO 80% target. [18] The 18 African countries audited include: 
Angola; Benin; Burkina Faso; Cameroon; Central African Republic; Ethiopia; Gambia; Ghana; 
Guinea-Bissau; Ivory Coast; Malawi; Mali; Niger; Sao Tome and Principe; Senegal; Togo; 
Uganda and Zambia. [18] According to the WHO 2010 world health statistics, access to selected 
generic medicines which include anti-malarial treatment was on average 57% in the private 
sector of the 15 countries audited as shown in figure 1. [42] Access in the public sector was on 
average 39.1% in the 14 audited countries (excluding South Africa).  [42]The traveller, through 
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medical/travel insurance or corporate sponsorship, may be in a privileged position to have 
access to private healthcare institutions (where they exist).  
 
 
 
In a study by Onwujekwe et.al. of 225 samples of anti-malarials (which included artesunate, 
dihydro-artemisnin, sulphadoxine-pyrimethamine, quinine and chloroquine) which were either 
collected or purchased in six Nigerian towns, it was found that 60 (37%) of the anti-malarials 
tested did not meet the United States Pharmacopoeia board specifications. [43] It was found that 
these drugs either contained sub-optimal quantities, or completely lacked in active ingredients. 
[43] What is surprising is that 78% of these drugs were obtained from private institutions in 
Nigeria. [43] In a study of artemisinin derivatives purchased in Kenya and the Democratic 
Republic of Congo by Atemnkeng et al., the percentage of active ingredient found ranged from 
23% to 81% for tablet and intra-muscular injection formulations respectively. [44] 
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Figure 1: Mean availability of selected generic medicines. 2001-2008 
Adapted from the WHO - World  Health Statistics 2010. 
(* Public sector not audited in South Africa) 
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Thus we may believe a traveller is receiving appropriate treatment for uncomplicated malaria, 
when in actual fact the traveller is at great risk of developing complicated malaria. As 
expatriates and long-term travellers by definition stay in malaria endemic areas for longer 
periods than short term travellers, they are more likely to run out of their personal supply of 
malaria chemoprophylaxis, and thus increase their chances of purchasing these suboptimal or 
counterfeit drugs in Africa. [35] Thus, although being compliant with chemoprophylaxis, they may 
be purchasing chemoprophylaxis which may have little or no active ingredients or even 
unwittingly buy inappropriate chemoprophylaxis containing active ingredients which the local 
malaria subtypes have shown resistance to.  
 
 
 
1.7 Fixed-wing air-ambulances in Africa. 
 
An air-ambulance is either dedicated (permanently configured for medical evacuations), or is a 
charted aircraft that is medically configured for a specific flight. [45] An air-ambulance may be a 
propeller driven or powered by a jet engine. This will restrict the aircraft in terms of range and 
landing capabilities, e.g. a jet cannot land on a gravel runway and requires amongst other things 
a tarred runway in good condition of a certain length (dependent on the ambient temperature), 
working runway lights, air traffic control, instrument landing capabilities and confirmation of fuel 
availability. Benefits of a jet aircraft is the ability to fly longer distances requiring fewer technical 
(fuel) stops, faster air speed resulting in a shorter mission time and having a pressurised cabin 
allowing for a controlled cabin altitude environment. The pressurised cabin is vital when flying 
patients with conditions where air is trapped in confined spaces for example pneumocephalus or 
bowel obstruction. The benefit of a propeller driven aircraft is the ability to land on shorter non-
tarred runways and thus have access to more remote areas in Africa. Propeller driven aircraft 
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may have an unpressurised cabin resulting in a less controlled cabin altitude environment and 
have a slower air-speed resulting in longer missions with potentially more technical stops. 
Several air-ambulance providers operate in Africa and are based in Angola, Botswana, Dakar, 
Gabon, Ivory Coast, Kenya, Namibia, Nigeria, South Africa, Sudan, Tanzania, Uganda, Zambia 
and Zimbabwe. These service providers vary in the type of fleet and staffing on the air-
ambulance. Some service providers are purely paramedic based and other service providers 
have a doctor on every flight. [45][46] Each air-ambulance flight by this particular reviewed air-
ambulance provider is staffed by a doctor and either a nurse trained in intensive care or an 
advanced life support paramedic. [46] This service provider has a fleet of three permanently 
configured dedicated air-ambulances, namely one Falcon 10 and two Lear Jet 35 aircraft which 
are based in Johannesburg, South Africa. [46] All three aircraft are fitted with a lifeport™ stretcher 
and the crew are able to provide a full intensive care unit (ICU) service including ventilation 
(non-invasive or invasive), defibrillation, cardiac pacing (internal or external), electric 
cardioversion, invasive blood pressure monitoring, multiple infusions of drugs through centrally 
placed lines, thrombolysis and advanced neonatal care. [46] An extensive range of equipment, 
with secondary back-up devices for all emergency equipment, as well as an array of essential 
medications are carried as standard on all flights. 
 
International accreditation for air medical transport is obtainable from the European Air Medical 
Institute (EURAMI) [47] and the Commission on Accreditation of Medical Transport Systems 
(CAMTS). [48] EURAMI is based in Germany and CAMTS is based in the United States of 
America. Both these accreditation services require accredited service providers to adhere to 
stringent standards on safety, education, training and ethics to ensure optimal patient 
management and safety during aeromedical transport. Three air-ambulance service providers in 
Africa are internationally accredited. The Johannesburg based air-ambulance service provider 
utilised for this study is the only CAMTS accredited service provider in Africa, and is also in the 
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process of obtaining EURAMI accreditation. [48] The remaining two internationally accredited 
service providers are based in Nairobi and Johannesburg respectively and are both accredited 
with EURAMI. [47] 
 
The air-ambulance service provider reviewed in this study is associated with the world’s leading 
international healthcare, medical assistance, and security services company. [41] In general, air-
ambulance missions are based on a fee for service agreement, whether through an insurance 
company, medical aid, corporate agreement or on a private basis. [41] 
 
This air-ambulance service provider has the ability to land in any (African) country depending on 
logistical issues mentioned above, security issues and obtaining flight clearances. Flights have 
been done to locations as far as Yemen, Dubai, Senegal, Egypt and Diego Garcia. Safety is a 
very real issue in Africa and the medical assistance company associated with the air-ambulance 
service provider in this study has a security branch based in London which continuously 
monitors the worlds’ security status in real time. [41] Security issues may restrict landing in a 
country completely or result in the inability to provide a bed-to-bed service for that specific 
country at that particular high security risk period. The bed-to-bed service may also be restricted 
in certain countries e.g. Nigeria where the flight on duty time of the pilots may result in having 
only one hour on the ground (time from landing to departure) if a direct turnaround is required. 
Should this time period be exceeded, the crew will have to spend an obligatory rest period in 
that country prior to departure as per the South African Civil Aviation Authority.  
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1.7.1 Process of air-ambulance flight activation. 
 
The medical assistance company associated with the air-ambulance provider utilised in this 
study will receive a call for assistance, whereupon medical information as well as the patient’s 
exact location is obtained as shown in figure 2. The reason for travel is usually documented by 
the alarm centre co-ordinator as this may assist with financial coverage decisions as certain 
insurance policies are only valid if the patient is for instance travelling for leisure and not for 
business reasons. In certain cases subcontractors may have coverage under the primary client 
so obtaining employment information is necessary. No information on reason for travel is 
required in private cases. 
 
The initial assessment and recommendation is made by the co-ordinating doctor, who is present 
24 hours a day in the alarm centre, and approved by the medical director of the medical 
assistance company. A decision is made on whether the patient requires an upgrade of care 
within the same town/city, country, to the closest appropriate regional medical hub in Africa, or if 
the medical condition warrants immediate activation of an air-ambulance to either Europe or 
South Africa. Once the decision is made for evacuation to South Africa, the case is handed over 
to the flight-desk which is staffed by a logistical coordinator and the flight-desk doctor.  
 
The flight desk acts as an air-ambulance service provider to the medical assistance company, 
and although the flight desk is associated with the medical assistance company it is an 
independent entity. The flight desk may receive a direct call for an air-ambulance request from a 
person/company with no association with the medical assistance company. In these cases the 
flight desk doctor and co-ordinator will assess the patients’ medical condition and logistical 
issues regarding current location. The most appropriate initial referral for stabilisation will be 
recommended where appropriate, whilst activating an air-ambulance.  
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     Incoming call 
 
 
 
Figure 2: Operational overview of aeromedical movements. 
 
 
As illustrated in figure 3 the mission is monitored by real-time satellite tracking of the air-
ambulance. The flight crew call the flight-desk doctor in the alarm centre at multiple pre-
ordained times during the mission. Once the crew have assessed and stabilised the patient a 
medical update is given to the flight-desk doctor. Medical advice is provided by the flight-desk 
doctor and the medical director in certain situations. Satellite phones are available on each flight 
Medical 
information and 
location obtained 
Decision made  
on aeromedical 
movement  
Case handed 
over to the flight 
desk  doctor and 
logistical co-
ordinator 
Flight desk co-
ordinates flight 
logistics and 
dispatches crew 
Flight desk 
monitors 
logistical and 
medical aspects 
of flight 
Flight desk 
doctor obtains 
post flight 
medical report 
from receiving 
facility 
Flight desk hands 
case over to 
medical 
assistance 
company for  
further medical 
monitoring  
Medical 
assistance 
company 
receives request 
for assistance 
22 
 
for in-flight emergencies. Upon landing the flight crew provide a medical update and again once 
handover is completed at the receiving facility. A post flight medical report is obtained by the 
flight-desk doctor from the receiving physician 1-2 hours after handover to allow for the majority 
of investigations to be completed. Depending on the client agreement, continuous medical 
monitoring may be provided until the time of discharge and/or repatriation to the patients’ 
country of residence where required. Should extended medical monitoring be required, the case 
is handed over to the co-ordinating doctor in the alarm centre once the post-flight medical report 
has been obtained. 
 
Figure 3: Example of real-time satellite tracking of a mission to Abuja, Nigeria. 
 
 
1.7.2 Language barriers experienced by flight crew. 
 
Air-ambulance evacuations out of Africa may be challenging as language barriers may restrict 
communication between the flight crew and the referring health care worker. Handover may be 
taken at either the referring hospital or at the airport, the latter in cases where there are security 
concerns or time constraints due to restricted flight-on-duty time of the pilots. These handovers 
are often undertaken without the benefit of a translator. 
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In certain situations no medical records may be available for the flight crew to review. As 
expatriates may not be fluent in English, this may present another hurdle in obtaining detailed, if 
any, information. 
 
 
 
1.8 The need for upgrade of care in sub-Saharan Africa. 
 
 
1.8.1 Identification of the nearest centre of medical excellence in sub-Saharan Africa. 
 
The medical assistance company referred to in this study has a Global Assistance Network 
(GAN) which utilises a credentialing process based on assessments of individual medical 
practitioners and medical facilities worldwide. [49] 
The GAN incorporates regular on-site inspections and surveys of clinics and hospitals to 
evaluate staff accreditation, equipment, sanitation and sterilisation techniques, laboratory 
equipment, staffing capabilities, origin of medication procurement and adherence to First World 
standards. A hospital or clinic may be deemed adequate to treat uncomplicated malaria, 
however when complications occur, these same facilities may be deemed substandard due to 
lack of ICU facilities or access to ancillary services such as haemodialysis. 
 
Patients may be temporarily moved to one of these accredited regional medical hubs and then 
have a secondary movement either to South Africa or Europe if the severity of the medical 
condition outweighs the capabilities of the centre concerned. 
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In cases where a patient is geographically closer to Europe the patient may be evacuated to the 
nearest centre of medical excellence (NCME) in Europe where feasible. The major limiting 
factors are the availability of European air-ambulance service providers as well as visa 
restrictions, often necessitating the activation of the Johannesburg based provider. Despite 
being geographically closer to Europe, patients are often evacuated to South Africa as the 
patient reaches a centre of medical excellence sooner (often days) than if a flight to Europe had 
been waited for. Flights by the Johannesburg service provider to Europe will be restricted by 
visa requirements by the flight crew and pilots as European countries make no exception on 
visa requirements even in the emergency air-ambulance evacuation scenario. The same visa 
restrictions also restrict patients from obtaining emergency care in Europe. The South African 
Customs and Immigration Department issues a three month emergency medical visa on landing 
in South Africa, regardless of the patients’ passport nationality, thus making South Africa a 
feasible destination in emergency situations. [50]In all cases the medical assistance company will 
look at the safest and fastest mode of evacuation to the most appropriate receiving facility. 
Where applicable, clients are presented with quotations and timelines of several different air-
ambulance service providers to both European destinations and South Africa. The medical 
assistance company will advise the client on the urgency of the mission and which option would 
be the most appropriate. However in these circumstances, the decision on destination and 
which provider to utilise will rest with the client. Due to the air-ambulance service provider 
reviewed in this study being based in Johannesburg, the majority of missions will be flown to 
Johannesburg, South Africa as the NCME.  
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1.8.2 The need for fixed-wing air-ambulance evacuation to the NCME in sub-Saharan                                      
          Africa. 
 
A cohort study published in 2006 by Patel et al. over a period of one year (dates not specified), 
of 2020 British Foreign and Commonwealth Office staff and partners living abroad in Europe, 
Americas, Africa, Near East, Middle East, Asia, South Pacific and Australasia measured the 
incidence of illness or injury serious enough to require consultation with a doctor. [33] Ages 
ranged from 23 to 59 years with a mean age of 42 ±9.6 years. 43 (2%) of the 2020 patients 
required medical repatriation. One of these 43 repatriated patients was also grouped under the 
listing of ‘certain infectious and parasitic diseases’ as a diagnosis. A total of 55 patients were 
grouped under the ‘certain infectious and parasitic diseases’ diagnosis, with six of these cases 
requiring hospital admission. [33] Four cases of malaria were reported, with an estimated malaria 
incidence of 1% in malaria endemic countries. This low incidence is thought to be due to urban 
postings and effective pre-travel advice. [33] No definition was given for medical repatriation, and 
whether it implied fixed-wing, rotor-wing or medically escorted commercial air travel. No 
breakdown was given for the countries where the repatriation originated from, or what the 
destination country was and may thus not have involved Africa at all.  
 
A study by Duchateau et al. reviewed all repatriation and evacuation records of a medical 
assistance company based in France. Medical movement was required by 402 patients during 
the period from August 2006 through July 2007.[51] Of the 402 patients 35 required urgent 
evacuation by air-ambulance with 15 (43%) of these originating out of sub-Saharan Africa. A 
further 367 patients required non-urgent medical movement, of which 69 patients were flown by 
air-ambulance mainly for logistical reasons, and the remaining 298 patients by a medically 
escorted commercial flight. 34 (9%) of the 367 non-urgent flights originated out of sub-Saharan 
Africa. Specific sub-Saharan countries of air-ambulance evacuation origin were unfortunately 
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not noted. Although no specific mention was made of the countries where the patients were 
evacuated to, the authors advised that patients were evacuated to the nearest centre where 
First World facilities were available. [51] The authors noted that the only country in sub-Saharan 
Africa with First World sanitary conditions was South Africa. [51][42] The medical assistance 
company in this study utilised their so called ‘Marco Polo’ program for evaluating medical 
facilities worldwide. According to this system, medical facilities with a high standard are limited 
to South Africa, Kenya and Ethiopia in sub-Saharan Africa. [51] 
 
A paucity of published data exists on fixed-wing air-ambulance evacuations out of Africa for 
malaria as well as malaria incidence in long-term travellers and expatriates. 
 
 
 
1.9 Overall aims of the study. 
 
The aim of this study is to review the characteristics of patients (expatriates and long-term 
travellers) with suspected malaria being evacuated by fixed-wing air ambulances out of sub-
Saharan Africa to Johannesburg, South Africa. 
 
 
 
1.10 Study objectives. 
 
The objectives of this study are to: 
 Determine the number of long-term travellers and expatriates who required fixed-wing air-
ambulance evacuation for suspected malaria out of sub-Saharan Africa. 
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 Compare the initial diagnosis of suspected malaria based on pre-dispatch information with 
the diagnosis at the receiving facility and thus determine the accuracy of the initial 
diagnosis.  
 Determine the number of suspected malaria patients who are utilising malaria 
chemoprophylaxis as well as the type of chemoprophylaxis utilised and the compliance rate 
of the patients.  
 Identify the presence of seasonal trends when compared to the specific countries wet and 
dry seasons. 
 Determine the number of suspected malaria patients who require definitive airway 
management as well as the mortality rate as a marker of disease severity. 
 Determine the incidence of specific malaria species as diagnosed at both the referring and 
the receiving facilities and to identify cases where the species isolated differed between the 
two facilities. 
 Document patient demographics including age, gender and reason for travel. 
 To assess the severity of malaria by documenting the clinical parameters of the suspected 
malaria patients. These parameters include the initial temperature, systolic blood pressure 
(SBP), blood glucose, heart rate, oxygen saturation, Glasgow Coma Scale (GCS), clinical 
anaemia, haemoglobin (Hb) level, clinical jaundice, average hourly urine output and 
presence of macroscopic haemoglobinuria. 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
All adult expatriate and long-term traveller patients, evacuated by fixed wing air-ambulance from 
a sub-Saharan African country to Johannesburg, South Africa with suspected malaria were 
included in the study.  
 
Patients with suspected malaria were identified by reviewing all flight records for the period 1 
July 2006 through 30 June 2009: 
1. Patients with an initial air-ambulance dispatch diagnosis of suspected malaria, which 
was based on either a clinical picture indicative of malaria (without any confirmatory 
testing or even with an initial negative RDT or blood film), or a positive RDT or a 
positive blood film.  
2. Any additional patients where the flight crew suspected malaria in the differential 
diagnosis were followed up. 
3. Any additional patients with a fever or documented clinical signs which could fit in 
with a diagnosis of malaria were followed up.  
 
Where documented in the post-flight medical report, the final diagnosis and malaria species 
isolated at the receiving facility were extracted. 
 
No patient identifying information was utilised in this retrospective study and therefore informed 
consent from the patients was not required and not obtained. Permission from the air-
ambulance provider management to utilise their flight records to complete the study was 
obtained. Ethics approval was obtained from the Witwatersrand Human Research Ethics 
Committee (Medical), clearance certificate reference: M10591.  
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2.1 Study design. 
 
This is a descriptive observational retrospective study. 
 
 
 
2.2 Study population. 
 
Patients were identified during the period 1July 2006 through 30 June 2009. This time period 
was chosen as the electronic data storage system used by the air-ambulance service provider 
was upgraded resulting in limited to no access to the stored data prior to this period.  
 
 
2.2.1 Inclusion criteria: 
 
All expatriates and long-term travellers aged 18 years and older, with suspected malaria in sub-
Saharan Africa where a fixed-wing air-ambulance to Johannesburg, South Africa was 
dispatched during the study period were included. 
 
Expatriates were defined as: 
 Non-immune individuals who reside for a period in a malaria-endemic country other than 
their original country of citizenship, with the purpose of completing an occupational 
(mainly) assignment, with the intent to return to their home country once the assignment 
period is completed. 
 Nationality for the purpose of this study, was based on the nationality of the passport 
held by the patient. Thus patients born in malaria-endemic countries who had emigrated 
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to non malaria-endemic countries and were in possession of a passport from the new 
country of residence were seen as expatriates due to limitation of flight documentation to 
the contrary. These previously semi-immune travellers have lost (part of) their immunity 
during stays of six months or more in non-endemic areas.[52] 
 
Long-term travellers were defined as: 
 Non-immune individuals who travelled to malaria-endemic countries for a period of 
seven days or longer.  
 
The diagnosis of suspected malaria was determined by: 
 Patients with an initial air-ambulance dispatch diagnosis of suspected malaria, which 
was based on either a clinical picture indicative of malaria (without any confirmatory 
testing or even with an initial negative RDT or blood film), or a positive RDT or a positive 
blood film.  
 Any additional patients where the flight crew suspected malaria in the differential 
diagnosis were followed up and included. 
 Any additional patients with a fever or documented clinical signs which could fit in with a 
diagnosis of malaria were followed up and included if the final diagnosis was confirmed 
as malaria.  
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Table 1: List of sub-Saharan countries (Highlighted countries are malaria-free) 
 
    Angola Equatorial Guinea Mali Somalia 
Benin Eritrea Mauritania (South Africa) 
Botswana Ethiopia Mauritius Sudan 
Burkina Faso Gabon Mozambique Swaziland 
Burundi Ghana Namibia Tanzania 
Cameroon Guinea Niger The Gambia 
Cape Verde Guinea-Bissau Nigeria Togo 
Central African Republic Ivory Coast Réunion Uganda 
Chad Kenya Rwanda Western Sahara 
Comoros Lesotho Sao Tome and Principe Zambia 
Congo  Liberia Senegal Zimbabwe 
Democratic Republic of Congo Madagascar Seychelles   
Djibouti Malawi Sierra Leone   
List adapted from: http://www.uis.unesco.org/profiles/EN/EDU/countries40350.html 
 
 
2.2.2 Exclusion criteria: 
 
 Semi-immune patients were excluded: 
Local nationals who have grown up in malaria-endemic areas and thus have a degree of 
malaria immunity due to repeated exposure to malaria. 
 The nationality was based on the nationality of the passport. 
 Patients with local African passports were assumed to live in the area due to 
limitation of flight documentation to the contrary. 
 Missions where an alternative air-ambulance service provider was utilised by the air-
ambulance provider utilised in this study were excluded due to limited access to in-flight 
medical records. 
 Internal (fixed-wing air-ambulance movement within the same country) evacuations were 
excluded as they did not meet inclusion criteria. 
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 Cases where the receiving facility destination was not Johannesburg, South Africa were 
excluded.  The air-ambulance provider utilised in this study was based in Johannesburg, 
South Africa and thus Johannesburg was expected to be the final destination.  
 
 
 
2.3 Data captured. 
 
The following parameters were collected from the flight records of a Johannesburg based 
internationally accredited fixed-wing air-ambulance service provider: 
 
 The date of the mission, the country of air-ambulance evacuation origin and final 
destination.  
 The initial air-ambulance dispatch diagnosis, the flight crew diagnosis and the receiving 
facility final diagnosis. 
 The reason for travelling which was grouped into business/occupational and leisure. 
 Patient demographics included age, gender, weight, nationality, travel history to malaria 
endemic areas in the past three months, malaria chemoprophylaxis utilisation, type of 
chemoprophylaxis utilised and the compliance thereof.  
 The method of initial malaria diagnosis (RDT, blood film or clinical) as per the referring 
facility. 
 Plasmodium species identified at both the referring and receiving facilities. 
 Initial clinical data included the temperature, systolic blood pressure, blood glucose, 
heart rate, oxygen saturation, GCS, clinical anaemia, haemoglobin (Hb) level, clinical 
jaundice, average hourly urine output and presence of macroscopic haemoglobinuria. 
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 Any anti-malarial treatment administered during the flight (intravenous, intramuscular or 
oral anti-malarials). 
 Definitive airway requirements and mortality at any stage of the mission was 
documented as a marker of severity. Decreased cerebral function with a decreased level 
of consciousness results in the loss of the ability to protect the airway necessitating 
intubation. Severe respiratory compromise will require intubation for ventilatory support. 
 
 
 
2.4 Statistical analysis. 
 
Data from case records for missions undertaken within the study period (1st July 2006 through 
30th June 2009), were captured on the Microsoft® Office Word® 2007 data capture sheet in 
hard copy retrospectively. 
Microsoft® Office Excel ®2007 was utilised for data entry from the data capture sheet into the 
data entry sheet. 
Analysis was performed with EpiInfo™ version 3.5.1. Continuous variables were summarised as 
frequencies and percentages as well as means and standard deviations for age, weight, GCS, 
systolic BP, Hb level, heart rate, hourly urine output, temperature, blood glucose level, oxygen 
saturation and respiratory rate. Discrete variables were expressed as frequencies and 
percentages for gender, the reason for travel, nationalities, utilisation of chemoprophylaxis, 
compliance on chemoprophylaxis, clinical jaundice, clinical anaemia and the presence of 
macroscopic haemoglobinuria. The P-fisher exact score was utilised for assessing the statistical 
significance when comparing the intubation requirements for patients who had utilised 
chemoprophylaxis against the patients who had not utilised chemoprophylaxis as well as where 
chemoprophylaxis utilisation was not documented. 
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CHAPTER 3: RESULTS 
 
A total of 997 patients were flown by fixed wing air-ambulance during the study period from 1st 
July 2006 through 30th June 2009. 679 patients complied with inclusion criteria and 318 patients 
were excluded. As more than one exclusion criteria may be relevant per excluded patient, for 
example in the case of a paediatric national patient, the exclusion criteria was applied in the 
order of the listed exclusion criteria as shown in table 2. 
 
 
Table 2: Reasons for exclusion of patients. 
  
   Flights    
      Excluded 318 
           Aged less than 18 years 
 
91 (28.6%) 
          Local nationals 
 
171 (53.8%) 
          Internal flights within South Africa 
 
41 (12.9%) 
          Origin of evacuation not from sub-Saharan Africa 
 
12 (3.8%) 
          Patients flown to their home countries from Johannesburg 
 
2 (0.6%) 
          Destination not Johannesburg 
 
1 (0.3%) 
         Included  679 
   Total flights 997 
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3.1 Flight demographics. 
 
3.1.1 Sub-Saharan countries of evacuation origin for all air-ambulance flights. 
 
The 679 patients included in the study population were flown out of 30 of the 49 (excluding 
South Africa) sub-Saharan African countries which are listed in table 2. Angola and Zambia 
were the countries of origin in 272 (40.1%) of all 679 sub-Saharan fixed wing air-ambulance 
evacuations as shown in figure 4.  
 
 
 
3.1.2 Initial diagnosis at time of air-ambulance dispatch. 
 
Figure 5 illustrates that malaria was the most common specific dispatch diagnosis, with 81 
(11.9%) of the 679 flights due to an initial diagnosis of suspected malaria. Cardiac patients 
encompassed 124 (18.3%) of all patients flown and included a range of pathologies: 
dysrythmias, myocardial infarctions, angina and cardiac failure amongst others. 164 (24.2%) of 
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Figure 4: Sub-Saharan countries of evacuation origin for all air-ambulance flights. 
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the 679 patients, were flown for other medical diagnoses. A total of 157 (23.1%) trauma related 
patients, 139 (20.5%) surgical patients and 14 (2.1%) obstetric patients were flown during the 
study period.  
 
 
 
 
 
3.1.3 Sub-Saharan countries of evacuation origin for suspected malaria air-ambulance 
flights. 
 
As shown in figure 6 the five most common sub-Saharan countries of origin for air-ambulance 
flights for patients with suspected malaria on dispatch were Angola 20 (24.7%), the Democratic 
Malaria 11.9% 
Trauma 23.1% 
Obstetric 2.1% 
Medical (other) 
24.2% 
Cardiac 18.3% 
Surgical 20.5% 
Figure 5: Initial diagnosis at time of air-ambulance dispatch. 
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Republic of Congo 15 (18.5%), Mozambique 13 (16.0%), Nigeria seven (8.6%) and Zambia six 
(7.4%). 
 
 
 
 
 
3.1.4 Proportion of suspected malaria flights of the total flights per sub-Saharan African     
         country. 
 
Figure 7 illustrates the proportion of suspected malaria flights of the total flights flown, with the 
following countries showing the highest proportions: Equatorial Guinea (100%); the Democratic 
Republic of Congo (26.8%); Ghana (25%); Mozambique (24.5%); Congo (20%) and Cameroon 
(18.2%). 
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Figure 6: Sub-Saharan countries of evacuation origin for suspected malaria cases. 
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3.2 Comparison of initial diagnosis of suspected malaria with flight crew and final   
      diagnosis.      
 
Eighty-one cases were dispatched with an initial diagnosis of malaria and in one additional case 
the flight crew made the diagnosis of malaria after their initial assessment of the patient. The 
latter patient was flown from the Democratic Republic of Congo with an initial diagnosis of acute 
renal failure and jaundice and had had an initial negative RDT at the referring facility. After 
clinical assessment, the flight crew suspected malaria and repeated the RDT which was positive 
without documentation of the species isolated. There were no cases of a receiving hospital 
making the first diagnosis of malaria. Of the 82 cases, nine did not have a final diagnosis 
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Figure 7: Proportion of suspected malaria flights compared to all flights flown per 
sub-Saharan African country of evacuation origin. 
All flights
Suspected malaria flights
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documented at the receiving facility. Of these nine cases, one case did not have a documented 
initial method of malaria diagnosis, two cases were diagnosed on clinical symptoms alone and  
five cases had an initial diagnosis based on a positive blood film at the referring facility. A single 
case of an in-flight mortality was attributed to severe complicated malaria where the diagnosis 
was based on an initial 4+ (>0.1% parasitaemia) P. Falciparum positive film test, and so no 
confirmatory testing was done at the receiving facility. 12 cases were omitted from the 
confirmed malaria group as malaria was excluded at the receiving facility in Johannesburg. As 
illustrated in table 3, the final diagnosis in these 12 cases included trypanosomiasis, tick bite 
fever, viral encephalitis, tuberculous meningitis, appendicitis, diverticulitis, anaemia, cardiac 
pathologies and lower respiratory tract infections.  
 
Table 3: Comparison of initial diagnosis of suspected malaria with final diagnosis at the receiving facility. 
      (n) Confirmed malaria (n) Not malaria (n) 
Diagnosis confirmed as malaria at receiving facility 61 61 
 Diagnosis not documented at receiving facility 9 
         Initial diagnosis based on positive smear 
 
5 
        Mortality in flight 
 
1 
        Initial diagnosis based on clinical signs alone 
  
2 
       No initial method of diagnosis documented 
  
1 
Diagnosis not malaria at receiving facility 12 
          Trypanosomiasis 
  
1 
        Tick bite fever 
  
1 
        Viral encephalitis 
  
2 
        Tuberculous meningitis 
  
1 
        Appendicitis 
  
1 
        Diverticulitis 
  
1 
        Anaemia 
  
1 
        Cardiac pathologies 
  
2 
        Lower respiratory tract infections 
  
2 
Total 82 67 15 
 
 
The flight crew differed with the dispatch diagnosis of malaria in four cases, all of which were 
confirmed as not being malaria at the receiving hospitals. 61 of the cases had malaria confirmed 
by blood film at the receiving facility, with a total of 67 cases being grouped under the final 
confirmed malaria cases.  
40 
 
3.3 Accuracy of initial method of malaria diagnosis. 
 
The method of initial malaria diagnosis at the referring facilities was based on blood films in 51 
(61.4%) patients, RDTs in 13 (15.9%) patients, and clinical signs alone in 14 (16.9%) patients 
as shown in table 4. 
 
Table 4:   Accuracy of initial method of malaria diagnosis based on receiving facility final diagnosis. 
    Initial diagnostic method         n 
 
Malaria confirmed  
n (%) Not malaria Not documented 
Blood smear                               51 40 (78.4%) 5 (9.8%) 6 (11.8%) 
RDT                                            13 12 (92.3%) 1 (7.7%) 
 Clinical                                        14 6 (42.8%) 6 (42.8%) 2 (14.2%) 
Not documented                          4 3 (75%) 
 
1 (25%) 
 
 
Of the 51 patients with an initial malaria blood film positive diagnosis, the diagnosis at the 
receiving facility was confirmed in 40 (78.4%) patients, excluded in five (9.8%) patients and not 
documented in six (11.8%) patients. One of the six patients  died in-flight with no confirmatory 
malaria testing performed at the receiving facility. 
 
The most accurate method of initial diagnosis appeared to be RDTs  with the use of clinical 
signs alone as the least accurate. 
 
 
3.4 Incidence of specific malaria species.  
 
P. falciparum alone, or in combination with other Plasmodium species was the most commonly 
isolated species. Of the patients with a documented species, 28 (100%) of the patients at the 
referring facilities and15 (88.2%) of the 17 patients at the receiving facilities demonstrated P. 
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falciparum (alone or in combination). Forty-four (53.7%) of the 82 suspected malaria cases had 
no species isolation documented in the post-flight medical report as shown in table 5. 
 
Table 5: Malaria species incidence. 
  
   Species isolation Pre-dispatch  Receiving facility 
P. falciparum 25 (30.5%) 13 (15.9%) 
P. falciparum and P. ovale 2 (2.4%) 1 (1.2%) 
P. falciparum and P. malariae 1 (1.2%) 1 (1.2%) 
P. ovale and P. vivax 
 
1 (1.2%) 
Not otherwise specified - mixed 
 
1 (1.2%) 
Not tested (clinical) 7 (8.5%) 
 Species not documented 40 (48.8%) 44 (53.7%) 
Negative film 4 (4.9%) 9 (11.0%) 
Negative RDT 3 (3.7%) 
 Diagnosis not malaria 
 
12 (14.6%) 
 
P. falciparum was diagnosed in combination with P. ovale in two patients originating out of 
Nigeria and Madagascar respectively. The patient from Nigeria had a confirmatory film at the 
receiving hospital for both strains. Receiving facility species was not documented for the patient 
originating out of Madagascar. 
 
P. malariae in combination with P. falciparum was diagnosed in 1 patient originating out of 
Mozambique, without confirmatory species isolation documentation at the receiving hospital.  
 
A patient originating out of Uganda had an initial diagnosis of blood film positive for P. 
falciparum, whereas the blood film at the receiving facility isolated a combination of P. ovale and 
P. vivax and no P. falciparum. 
 
Two patients flown out of Angola with an initial blood film diagnosis of P. falciparum malaria had 
different strains isolated at the receiving hospitals. In one patient P. malariae was also seen on 
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the film, and the other patient had a film which was documented as ‘not otherwise specified 
mixed’ at the receiving facility. 
 
3.5 Seasonal trends of suspected malaria flights. 
 
 
 
April and June showed the highest incidence of suspected malaria cases being evacuated, with 
13 (15.9%) and nine (11.0%) of all suspected malaria evacuations being flown in these months 
respectively over the three year period as shown in figure 8.  
 
 
3.5.1 Seasonal trends of specific countries. 
 
When considering the seasonal variation of malaria, the rainfall pattern of the region concerned 
needs to be taken into consideration. Each sub-Saharan African country has unique geography 
and climate variations resulting in specific seasonal variances as pertains to wet and dry 
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Figure 8: Monthly air-ambulance flights per year for suspected malaria cases. 
2006 to 2007
2007 to 2008
2008 to 2009
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seasons. The five countries most frequently flown to as the country of origin for suspected 
malaria cases were reviewed individually with regards to seasonal trends. 
 
 
Angola 
Ten (50%) of suspected malaria flights originating out of Angola were flown during the wet 
season, although cases were flown steadily throughout the year. A peak of five (25%) of all 
Angolan flights occurred during the month of June, which falls within Angola’s dry season. 
 
 
 
 
The Democratic Republic of Congo 
All cases originating out of the Democratic Republic of Congo during this study period were 
flown out of either Kinshasa or Lubumbashi which are both situated in the south of the 
Democratic Republic of Congo. Although one patient was flown out of Zambia, the actual initial 
malaria diagnosis was made in the Democratic Republic of Congo and was thus included in the 
Democratic Republic of Congo group when considering seasonal trends. 
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Figure 9: Monthly air-ambulance flights to Angola per year. 
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Five (31.3%) of the Democratic Republic of Congo cases were flown during the southern 
regions wet season (November through March). The peak however, occurred during April and 
May (dry season) with seven (43.8%) of all the cases occurring during this period. 
 
 
 
 
Mozambique 
The malaria cases flown out of Mozambique were widely distributed throughout the year. Four 
(30.8%) of the malaria flights originating out of Mozambique occurred during the country’s rainy 
season. 
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Figure 10: Monthly air-ambulance flights to the Democratic Republic of Congo 
per year. 
2006 to 2007
2007 to 2008
2008 to 2009
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Figure 11: Monthly air-ambulance flights to Mozambique per year. 
2006 to 2007
2007 to 2008
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Nigeria 
Four (57.2%) of the flights fell within the wet season, although the highest single month was 
November with two (28.6%) of the flights occurring here.  
 
 
 
 
Zambia 
Six (100%) of the suspected malaria evacuations originating out of Zambia occurred within the 
wet, humid season. 
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Figure 12: Monthly air-ambulance flights to Nigeria per year. 
2006 to 2007
2007 to 2008
2008 to 2009
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Figure 13: Monthly air-ambulance flights to Zambia per year. 
2006 to 2007
2007 to 2008
2008 to 2009
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3.5.2 Seasonal trends of all suspected malaria flights. 
 
As shown in figure 14, no seasonal trend was evident when comparing suspected malaria flights 
flown during specific country’s wet and dry seasons. Of the 82 flights, 42 (51.2%) of flights were 
flown during the specific country’s wet seasons. 
 
 
 
 
3.6 Suspected malaria patient demographics. 
 
Age ranges, gender and the reason for travelling for all the flights as well as for suspected and 
confirmed malaria flights are shown in table 6. The weight of the suspected malaria patients 
ranged from 53 to 125 kg with a mean weight of 79.9 ±SD 15.9 kg.  
 
Travel history 
Travel history to malaria-endemic countries (other than the malaria-endemic sub-Saharan 
country of air-ambulance origin) in the preceding three months was obtained from 19 of the 
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Figure 14: Seaonal trends of suspected malaria flights per country of 
evacuation origin. July 2006 through June 2009. 
Wet season
Dry season
47 
 
suspected malaria patients and not documented in the remaining 63 patients. The reason the 
travel history was documented was to ascertain whether patients could potentially have been 
exposed to malaria species other than the species expected for the country from which they 
were evacuated.  Of the 19 patients, five had confirmed travelling to other malaria-endemic 
countries in the preceding three months, which are listed in brackets after the country of air-
ambulance evacuation origin. These countries included: Nigeria (“tropical areas”), Ghana 
(Nigeria), Angola (Cameroon), Zambia (the Democratic Republic of Congo) and Angola (China -
province not specified). None of these five patients had documented Plasmodium species that 
were atypical for the country of diagnosis. 
 
Table 6: Summary of patient demographics   
     All flights (n=679)  Suspected malaria  (n=82) Confirmed malaria (n=67) 
Age  
       18-30 years 86 (12.7%) 17 (20.7%) 13 (19.4%) 
    31-40 years 151 (22.2%) 18 (22.0%) 15 (22.4%) 
    41-50 years 193 (28.4%) 26 (31.7%) 20 (29.9%) 
    51-60 years 181 (26.7%) 13 (15.9%) 12 (17.9%) 
    61-70 years 45 (6.6%) 8 (9.8%) 7 (10.4%) 
    >70 years 23 (3.4%) 
      Mean age 45.8 ±12.7 years  42.1 ±12.8 years 42.9 ±12.8 years 
    Range 18-89 years 18-68 years 18-68 years 
    Gender 
       Male 538(79.2%) 69 (84.1%) 56 (83.6%) 
    Female 141 (20.8%) 13 (15.9%) 11 (16.4%) 
    
Reason for travel    
    Business/occupation 405 (59.6%) 65 (79.3%) 54 (80.6%) 
    Leisure 48 (7.1%) 1 (1.2%) 1 (1.5%) 
    Not documented 226 (33.3%) 16 (19.5%) 12 (17.9%) 
 
 
Nationality 
Table 7 reflects the various nationalities of the patients evacuated for suspected malaria during 
the three year period. The vast majority of patients were South African citizens in 40 (48.8%) of 
the 82 cases. 
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Table 7: Nationalities of suspected malaria patients.       
        American  4 (4.9%) 
 
Chinese  3 (3.7%) 
 
Japanese  1 (1.2%) 
Argentinean 1 (1.2%) 
 
Croatian  1 (1.2%) 
 
Korean  2 (2.4%) 
Australian  1 (1.2%) 
 
Filipino  1 (1.2%) 
 
Portuguese  5 (6.1%) 
Belgian  1 (1.2%) 
 
French  6 (7.3%) 
 
South African  40 (48.8%) 
Brazilian  1 (1.2%) 
 
Indian  1 (1.2%) 
 
Swiss  1 (1.2%) 
British  7 (8.5%) 
 
Irish  1 (1.2%) 
 
Taiwanese  1 (1.2%) 
Canadian  1 (1.2%) 
 
Israeli  2 (2.4%) 
 
Thai  1 (1.2%) 
 
 
 
3.7 Malaria chemoprophylaxis utilisation and compliance. 
 
Of the 82 patients with an initial and flight crew diagnosis of suspected malaria, only 11 (13.4%) 
had utilised malaria chemoprophylaxis and 51 (62.2%) had not. Of the 20 (24.4%) patients 
where malaria chemoprophylaxis utilisation was not documented, six patients required 
intubation or had already been intubated by the referring facility, and a further two patients had 
a GCS of 13/15 and 11/15 respectively, and were therefore unable to provide a 
chemoprophylaxis history. 
 
Of the 11 patients who had utilised malaria chemoprophylaxis, two were non-compliant, two 
were compliant and there was no documentation on the other seven patients. The first non-
compliant patient stopped taking his chloroquine chemoprophylaxis one month prior to the 
malaria diagnosis in Angola due to side effects including gastro-intestinal symptoms and dry 
hands. The second non-compliant patient stopped taking his mefloquine chemoprophylaxis due 
to side effects including morning nausea and sleepiness one week prior to the malaria diagnosis 
in Madagascar.  
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The choice of chemoprophylaxis was appropriate for the country of origin in seven of the eight 
patients who had the type of chemoprophylaxis utilised documented by the flight crew. One 
patient originating out of Angola utilised chloroquine (Nivaquine®, Daramal®, Plasmaquine®, 
Rolab-Chloroquine®) as chemoprophylaxis. Mefloquine (Lariam®, Mefliam®) was the most 
popular chemoprophylaxis choice, and was utilised by four (36.4%) patients, followed by 
doxycycline (Vibramycin®, Doxitab®, Cyclidox®) utilisation by two (18.2%) patients. 
Atovaquone-proguanil (Malanil®, Malarone®) was utilised by one (9%) patient.  The remaining 
three (27.3%) patients did not have the type of chemoprophylaxis documented.  
 
Two (18.2%) of the 11 patients who had utilised malaria chemoprophylaxis required intubation. 
The first patient was evacuated out of Angola during the wet month of November. As this patient 
was in severe respiratory failure with a respiratory rate of 50 breaths/min and oxygen saturation 
readings of 61% on supplemental oxygen the crew elected to intubate the patient emergently 
and obtained chemoprophylaxis information from a colleague post intubation. The colleague 
confirmed chemoprophylaxis compliance although the type of chemoprophylaxis utilised could 
not be recalled. The latter patient was evacuated out of Mozambique during the dry month of 
October. This patient had already been intubated by the referring facility and the accompanying 
medical records documented atovaquone-proguanil utilisation without mentioning compliance.  
 
Of the 71 patients where chemoprophylaxis was either not utilised or not documented, 13 
(18.3%) required intubation. The 13 patients were flown out of Angola, Congo, the Democratic 
Republic of Congo, Ghana, Mozambique, Nigeria and Madagascar with four of these flights 
during each specific country’s wet months and three during the country’s dry months as shown 
in table 8.   
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No statistically significant difference (P-Fisher exact = 0.50) was shown for intubation 
requirements when comparing patients who had utilised malaria chemoprophylaxis with the 
patients who had not, nor when comparing intubation requirements of patients who had utilised 
chemoprophylaxis with patients where chemoprophylaxis utilisation was not documented (P-
Fischer exact = 0.39). When comparing patients who had utilised malaria chemoprophylaxis 
with the patients who had not utilised chemoprophylaxis or where chemoprophylaxis was not 
documented, no statistically significant difference (P-Fischer exact = 0.68) was shown. 
 
 
Table 8: Intubation requirements compared to chemoprophylaxis utilisation. 
  
     Chemoprophylaxis utilised (11) 
  Air-ambulance country of origin 
Wet 
season 
Dry 
season 
       Intubated 2 (18.2%) Angola  1 
 
  
Mozambique  
 
1 
      Not intubated 9 (81.8%) 
   Chemoprophylaxis not utilised (51)         
      Intubated 7 (13.7%) Congo 1 
 
  
Democratic Republic of Congo 
 
1 
  
Madagascar 1 
 
  
Mozambique    
 
1 
  
Nigeria 2 1 
     Not intubated 44 (86.3%) 
   Chemoprophylaxis usage not documented (20)    
      Intubated 6 (30.0%) Angola 1 
 
  
Ghana 1 
 
  
Democratic Republic of Congo 2 1 
  
Mozambique    
 
1 
     Not intubated 14 (70.0%) 
    
Intubation requirements comparing chemoprophylaxis utilised vs. not utilised P-fisher = 0.50 
Intubation requirements comparing chemoprophylaxis utilised vs. not documented P-fisher = 0.39 
Intubation requirements comparing chemoprophylaxis utilised vs. not utilised/documented P-fisher = 0.68 
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3.8 Initial clinical parameters of suspected malaria patients. 
 
Glasgow Coma Scale 
As shown in table 9, the GCS ranged from 4/15 to 15/15 with a mean GCS of 14.2 ±2.1. The 
majority of the suspected malaria patients, 61 (74.4%) had an initial GCS of 15/15, and 13 
(15.9%) patients had an initial GCS of 9/15 to 14/15. The three (3.6%) patients with a GCS 
score of between 4/15 to 8/15 were all intubated by the flight crew for airway protection. 
 
Table 9: Summary of initial clinical parameters of suspected malaria patients 
  
      GCS n (%) Systolic BP n (%) Heart rate n (%) 
3/15: 0 70-90mmHg 5 (6.1%) <60bpm 2 (2.4%) 
4-8/15: 3 (3.6%)   91-110mmHg 21 (25.6%) 60-100bpm 60 (73.2%) 
9-14/15: 13 (15.9%) 111-130mmHg 29 (35.4%) 101-140bpm 18 (22.0%) 
15/15: 61 (74.4%) 131-150mmHg 21 (25.6%) >140bpm 2 (2.4%) 
Intubation in situ 5 (6.1%) >150mmHg 6 (7.3%) 
  
      Range 4-15/15 Range 77-180mmHg Range 46-150bpm 
Mean 14.2 SD ± 2.1 Mean 121.0 SD ±20mmHg Mean 88.9 SD ±  21bpm 
      Hb n (%) Hourly urine output n (%) Temperature n (%) 
< 5.0 g/dL 1 (1.2%) <0.5 ml/kg/hr 7 (8.5%) <37.5°C 61 (74.4%) 
5.0-7.0 g/dL 2 (2.4%) 0.5-1.0ml/kg/hr 10 (12.2%) 37.5-38.4°C 13 (15.9%) 
7.1-10.0 g/dL 9 (11.0%) 1.1-2.0 ml/kg/hr 13 (15.9%) >38.4°C 7 (8.5%) 
>10.0 g/dL 38 (46.3%) >2.0 ml/kg/hr 11 (13.4%) Not documented 1 (1.2%) 
Not documented 32 (39.1%) Self voiding - nil 33 (40.2%) 
  
  
Self voiding - passed 8 (9.8%) 
  
      Range 4.4-17.0 g/dL Range 0.2-24ml/kg/hr Range 35.4-39.8°C 
Mean 11.9 SD ±3 g/dL Mean 2.1 SD ±3.7ml/kg/hr Mean 37.0 SD ±1.0°C 
      
Blood glucose n (%) Oxygen saturation n (%) 
Respiratory 
rate n (%) 
<3.5 mmol/L 2 (2.4%) < 80% 2 (2.4%) 8-11/min 1 (1.2%) 
3.5-8.0 mmol/L 66 (80.5%) 80-90% 1 (1.2%) 12-20/min 56 (68.3%) 
>8.0 mmol/L 14 (17.1%) >90% 79 (96.4%) 21-29/min 19 (23.2%) 
    
≥30/min 6 (7.3%) 
      Range 2.4-31.2 mmol/L Range 61-100% Range 10-50/min 
Mean 6.7 SD ± 3.5 mmol/L Mean 96 SD ±5.1% Mean 19.7 SD ± 7.7/min 
      Clinical 
anaemia n (%) 
Macroscopic 
haemoglobinuria n (%) 
Clinical 
jaundice n (%) 
Yes 20 (24.4%) Yes 13 (15.9%) Yes 25 (30.5%) 
No 48 (58.5%) No 19 (23.2%) No 49 (59.8%) 
Not documented 14 (17.1%) Not documented 50 (60.9%) Not documented 8 (9.7%) 
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Systolic blood pressure 
Suspected malaria patients presented with a systolic BP ranging from 77 to 180mmHg with a 
mean of 121 ± 20 mmHg. Five (6.1%) of the 82 patients presented with systolic BP readings of 
equal or less than 90 mmHg. Two of these hypotensive patients had already been intubated by 
the referring facility upon flight crew assessment. Table 10 depicts the associated clinical 
parameters for the afore-mentioned five patients who presented with systolic BP readings of 
equal or less than 90 mmHg. 
 
Table 10: Clinical parameters of patients with an initial systolic BP ≤90mmHg. 
 
      SBP Heart rate GCS Urine output Clinical anaemia Hb 
90 mmHg 90 bpm 15/15 Spontaneous voiding x1/2.5hrs No N/D 
88 mmHg 82 bpm Intubated Nil spontaneous voiding/4hrs No N/D 
90 mmHg 80 bpm 15/15 Nil spontaneous voiding/2.5hrs Yes N/D 
77 mmHg 65 bpm 15/15 0.8 ml/kg/hr No 13.3 g/dL 
77 mmHg 128 bpm Intubated 0.2ml/kg/hr N/D 10.5 g/dL 
 
One of the five patients presenting with hypotension was on an adrenaline infusion of 
1.8mcg/kg/min from the referring facility in the Democratic Republic of Congo. This patient 
presented with a systolic BP of 77mmHg and heart rate of 128bpm and had already been 
intubated.  
One patient from Congo presented with a systolic BP of 91 mmHg on a dopamine infusion, 
without documentation of the infusion dose, which was changed to a combination of adrenaline 
and dobutamine infusions by the flight crew. The flight crew initiated inotropic infusions in a 
further five patients. One of the five patients was hypotensive on presentation and four patients 
became hypotensive during the evacuation necessitating inotropic support. The patient who 
died in-flight received adrenaline as part of the resuscitation as per Advanced Cardiac Life 
Support®  principles. 
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Heart rate 
The patients’ heart rates ranged from 46 to 150bpm with a mean of 88.9 SD ± 21 bpm. Two 
(2.4%) patients presented with bradycardias, defined as a heart rate of less than 60 bpm. The 
first patient developed a second-degree heart block with a heart rate of 46 bpm when 
intravenous quinine was initiated at the referring hospital in the Democratic Republic of Congo. 
The second patient, flown out of Madagascar, had a sinus bradycardia with an initial heart rate 
of 49bpm. This patient tolerated intravenous quinine administered during the flight. Both patients 
presenting with bradycardias had adequate peripheral perfusion. One patient who presented 
with an initial heart rate of 67 bpm in a sinus rhythm had apparently received atropine at the 
referring facility in Equatorial Guinea. This patient tolerated an intravenous quinine loading dose 
administered by the flight crew. Twenty patients presented with tachycardias, defined as a heart 
rate of more than 100 bpm. The two patients with the fastest heart rates both presented with 
sinus tachycardias of 149bpm and 150bpm respectively and had adequate peripheral perfusion 
and systolic blood pressures of more than 90mmHg. One of the 20 tachycardic patients 
presented with a systolic BP of 77mmHg. 
 
 
Haemoglobin level 
The Hb as measured by means of the i-STAT® blood gas analyser on initial assessment by the 
flight crew showed a range of 4.4-17 g/dL and a mean Hb of 11.9 SD ± 3.0 g/dL. The i-STAT® 
provides real-time laboratory results within two minutes. Quality control checks are performed 
utilising a metal electronic cartridge simulator prior to each air-ambulance flight as well as prior 
to utilisation. Of the 82 suspected malaria patients, nine (11%) patients had an initial Hb of 
between 7.1-10.0 g/dL with two of these patients having received three and two units of packed 
red cells (PRC) at the referring facilities in Cameroon and Malawi respectively prior to flight crew 
assessment as shown in table 11. Two (2.4%) patients had a Hb level of between 5.0 to 7.0 
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g/dL and neither had received blood transfusions at the referring facility nor from the flight crew. 
One (1.2%) patient flown out of the Democratic Republic of Congo had an initial Hb of 4.4 g/dL, 
and the flight crew administered two units of emergency O-negative packed red cells during the 
flight. For the purpose of this study anaemia was defined as a Hb level of less than 10 g/dL, 
thus 12 (14.6%) of the suspected malaria patients were anaemic. 38 (46.3%) patients had a Hb 
measurement of more than 10.0 g/dL with no documentation on a Hb measurement in the 
remaining 32 (39.0%) patients. 
 
Table 11: Clinical parameters of patients with a Hb <10.0 g/dL. 
 
      Hb (g/dL) SBP (mmHg) HR (bpm) Sats Intubation PRC transfusion 
4.4 160 112 99% No 2U by crew 
6.1 108 82 98% No 
 6.4 97 81 91% No 
 7.5 145 105 79% By flight crew 
7.8 127 109 98% No 2U at referring facility 
8.2 113 46 97% No 
 8.2 115 94 100% No 
 8.2 180 113 98% By flight crew 
8.5 110 75 100% No 
 8.8 157 72 97% No 
 8.8 99 149 99% No 
 9.2 118 69 100% No 3U at referring facility 
 
 
Clinical anaemia 
Clinical anaemia, as per assessment of the presence of pallor by the flight crew doctor, was 
present in 20 (24.4%) of the 82 suspected malaria patients, with 14 (70.0%) of these 20 patients 
having had a Hb level checked upon assessment. Of these 14 patients, four (28.6%) had a Hb 
level of more than 10 g/dL, seven (50.0%) had a Hb level of 7.1 to 10 g/dL, two (14.3%) had a 
Hb level of 5.0 to 7.0 g/dL and one (7.1%) patient had a critically low Hb of less than 4.4 g/dL. 
Thus in 10 (71.4%) of the 14 patients the blood gas analyser haemoglobin measurement 
confirmed the clinical diagnosis of anaemia. Two patients with Hb values of 7.5 and 8.2 g/dL 
respectively required intubation with the former patient dying during the flight. Of the 20 patients 
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who presented with clinical anaemia seven (35.0%) patients also presented with clinical 
jaundice and two (10%) patients also presented with macroscopic haemoglobinuria. 
 
Table 12: Clinical parameters of patients presenting with clinical anaemia. 
   
         
Hb (g/dL) 
SBP   
(mmHg) 
Heart rate  
(bpm) 
Oxygen 
saturation GCS Intubated 
Macroscopic 
haemoglobinuria 
Clinical 
jaundice 
Supplemental 
oxygen in 
situ 
4.4 160 112 99% 15 No N/D No No 
6.1 108 82 98% 15 No N/D No No 
6.4 97 81 91% 15 No No Yes No 
7.5 145 105 79% 8 By flight crew No Yes Yes 
7.8 127 109 98% 14 No N/D No No 
8.2 115 94 100% 15 No No Yes No 
8.5 110 75 100% 15 No No No No 
8.8 99 149 99% 14 No N/D No No 
8.8 157 72 97% 15 No N/D Yes No 
9.2 118 69 100% 15 No N/D Yes No 
10.5 122 67 100% 15 No No Yes No 
12.6 137 62 96% 15 No No Yes No 
12.9 112 83 100% 10 By flight crew N/D No No 
15.6 151 110 99% Intubated In situ Yes No Yes 
ND 118 76 97% 15 No Yes N/D No 
ND 117 75 96% 15 No No No No 
ND 113 78 93% 15 No No No No 
ND 135 72 98% 15 No No N/D No 
ND 90 80 94% 15 No N/D No No 
ND 107 62 99% 15 No No No No 
 
 
Macroscopic haemoglobinuria 
The presence of macroscopic haemoglobinuria as a sign of haemolysis was documented in 13 
(15.9%) of the suspected malaria patients, absent in 19 (23.2%) patients and not documented in 
the remaining 50 (60.9%) patients. Table 13 illustrates that concurrent clinical jaundice was 
present in five (38.5%) of the 13 patients with macroscopic haemoglobinuria. The Hb levels 
were higher  than 10 g/dL in all six patients who underwent testing and urine output was  more 
than 0.5 ml/kg/hr in all seven patients where hourly urine output was measured. The systolic BP 
was more than 90mmHg in all 13 patients with macroscopic haemoglobinuria. 
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Table 13 : Suspected malaria patients with macroscopic haemoglobinuria. 
 
     
Clinical jaundice Clinical anaemia Hb Urine output 
SBP 
(mmHg) 
Yes No N/D 3.2 ml/kg/hr 109 
No N/D 14.2 g/dL 2.7 ml/kg/hr 140 
Yes No 14.2 g/dL Spontaneous voiding x2/9hrs 142 
Yes N/D 10.9 g/dL 1.6 ml/kg/hr 113 
N/D N/D N/D Nil spontaneous voiding/4hrs 120 
Yes No N/D 4.7 ml/kg/hr 149 
No No N/D Nil spontaneous voiding/3hrs 102 
No No 11.2 g/dL 1.3 ml/kg/hr 132 
No Yes N/D Spontaneous voiding x1/6hrs 118 
No Yes 15.6 g/dL 1.0 ml/kg/hr 151 
Yes No N/D Nil spontaneous voiding/4hrs 147 
No No N/D Spontaneous voiding x1/4hrs 110 
No No 12.2 g/dL 0.7 ml/kg/hr 91 
 
 
Hourly urine output 
Oliguria, defined as an average urine output of less than 0.5ml/kg/hr was documented in seven 
(8.5%) of the suspected malaria patients. One of these seven patients had presented with 
concurrent initial hypotension with a systolic BP of 77mmHg. Urine output in the 41 patients 
where hourly urine output volumes were documented ranged from 0.2 to 24ml/kg/hr with a 
mean output of 2.1 ± 3.7ml/kg/hr.  
Of the 11 patients with polyuria, defined as urine output of more than 2.0ml/kg/hr, one patient 
had an output of 24ml/kg/hr and had received furosemide from both the referring facility and the 
flight crew. In this patient the crew diagnosis as well as the final diagnosis at the receiving 
facility was atrial fibrillation with congestive cardiac failure and not malaria. No patient 
presenting with polyuria had hyperglycaemia on initial assessment, and presented with blood 
glucose levels ranging from 3.9 to 8.2 mmol/l.  
 
 
Clinical jaundice 
Clinical jaundice was present in 25 (30.5%) patients and absent in 49 (59.8%) patients. No 
documentation regarding the presence or absence of jaundice was made in the remaining eight 
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(9.7%) patients. Macroscopic haemoglobinuria was present in five (20.0%) of the 25 clinically 
jaundiced patients, absent in six (24.0%) patients and not documented in the remaining 14 
(56.0%) patients. Of the 25 clinically jaundiced patients five (20.0%) had a Hb measurement of 
less than 10 g/dL with a range of 6.4 to 9.2 g/dL, 13 (52.0%) patients had a Hb measurement of 
more than 10 g/dL and the remaining seven (28.0%) patients did not have a Hb documented. 
 
 
Temperature 
The temperature readings of the suspected malaria patients ranged from 35.4-39.8ºC with a 
mean temperature of 37.0 SD ± 1.0 ºC. Seven (8.5%) of the 82 suspected malaria patients had 
an initial temperature higher than 38.4ºC. 
 
 
Blood glucose level 
The initial blood glucose levels as measured by finger prick testing ranged from 2.4 to 31.2 
mmol/L with a mean level of 6.7 SD ± 3.5 mmol/L. The two patients with the lowest blood 
glucose levels presented with values of 2.4 mmol/L and 2.9 mmol/L respectively. Both patients 
had received intravenous quinine infusions prior to flight crew arrival, and neither were on any 
glucose containing intravenous fluids at the time of assessment. Intravenous quinine was 
appropriately administered in a 5% dextrose infusion to the first patient during the flight from 
Angola as it was due, and the patient remained persistently hypoglycemic necessitating four 
administrations of 50ml 50% dextrose by the flight crew. A patient flown from the Democratic 
Republic of Congo presented with an initial blood glucose level of 31.2 mmol/L whilst on a 5% 
dextrose saline infusion. This patient was not known to have diabetes and required insulin 
during the flight after the dextrose infusion was stopped to control his blood glucose levels. 
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Oxygen saturation 
Upon assessment the suspected malaria patients’ oxygen saturation readings ranged from 61-
100% with a mean of 96.0 SD± 5.1%. The majority of patients, 79 (96.4%) presented with initial 
oxygen saturation readings of more than 90%. Three patients presented with initial oxygen 
saturation readings of less than 90%. Two of these patients were receiving supplemental 
oxygen at the time of assessment. The first patient from Angola had saturation reading of 61% 
and the second patient from the Democratic Republic of Congo had saturation readings of 79%. 
One patient from Ghana who presented with oxygen saturation readings of 84% was not on 
supplemental oxygen at the time of assessment. All three patients were subsequently intubated 
by the flight crew. In total, 19 (23.2%) of the 82 suspected malaria patients were receiving 
supplemental oxygen therapy at the time of initial assessment by the flight crew.  
 
 
Respiratory rate 
The respiratory rate ranged from 10 to 50 breaths per minute with a mean of 19.7 SD ± 7.7 
breaths per minute. As shown in table 14, six patients presented with marked tachypnoea, 
defined as a respiratory rate of equal/more than 30 breaths per minute. Of these six patients, 
three presented with oxygen saturation readings of less than 90% and four of the six 
tachypnoeic patients were intubated by the flight crew. 
 
Table 14: Initial clinical respiratory parameters in tachypnoeic patients. 
     Respiratory rate     
(breaths/min) 
Oxygen 
saturation 
Supplemental 
oxygen Intubation GCS 
32 99% Yes No 11 
36 97% Yes No 15 
36 100% No By flight crew 10 
46 79% Yes By flight crew 8 
47 84% No By flight crew 9 
50 61% Yes By flight crew 15 
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3.8.1 Intubation requirements. 
 
A total of 15 (18.3%) of the 82 patients in the suspected malaria group required intubation and 
ventilation as shown in table 15. Ten of these intubations were performed by the flight crew post 
initial patient assessment. All intubations performed by the referring facilities as well as the flight 
crew were orotracheal intubations.  
 
The indications for the 10 flight crew intubations were due to a depressed level of 
consciousness (GCS) in seven patients which ranged from 4/15 to 14/15, severe respiratory 
failure in one patient and a combination of depressed level of consciousness and respiratory 
failure in two patients. The remaining five patients had already been intubated by the referral 
facility prior to the flight crew arrival.  
 
Twelve of the 15 intubated patients had a final diagnosis of P. falciparum at the receiving facility. 
Two of these patients had been flown with an initial diagnosis of P. falciparum combined with P. 
ovale. One patient who had been flown out of the Democratic Republic of Congo with an initial 
diagnosis of P. falciparum had P. malariae identified at the receiving facility. P. vivax was 
identified in one patient flown out of Angola without a documented initial species identification 
from the referring facility. One patient died in-flight which was attributed to the 4+ P. falciparum 
film positive severe complicated malaria by the air-ambulance service provider. 
 
Patients requiring intubation by the flight crew were flown out of Nigeria, Ghana, Angola, 
Mozambique, Congo and the Democratic Republic of Congo. Six of these 10 flights were during 
the wet season for that specific country.  
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Thirteen of the 15 patients were receiving intravenous quinine as part of the treatment regimen 
from the referring facility and two patients did not have any documentation on the referring 
facility treatment regimens. The crew administered loading doses of intravenous quinine to the 
latter two patients and the next due dosage in a further seven patients. Five patients were not 
due their next intravenous quinine dose during the flight and no anti-malarials were 
administered to a patient where the crew differed with the referring facility diagnosis of malaria. 
The latter patient who was flown from Ghana was confirmed to have pneumonia at the receiving 
facility. Five patients were on concurrent antibiotics as part of the treatment regimen from the 
referring facility, including ceftriazone, cefuroxime and cefotaxime. Two patients were on 
inotropic support upon crew assessment, including one patient who was hypotensive despite 
being on an adrenaline infusion. The flight crew provided inotropic support to these two patients 
as well as a further three patients. Adrenaline was provided as part of the resuscitation of the 
patient who died in-flight. 
 
Of the five patients who were intubated by the referral facility one was hypotensive with a 
systolic BP of 77 mmHg, and three patients were tachycardic including the aforementioned 
hypotensive patient. All five patients presented with saturation levels of more than 90% on 
supplemental oxygen with artificial ventilation. Patients were flown out of Mozambique, Angola, 
Madagascar and the Democratic Republic of Congo as illustrated in table 15. Although one 
patient was flown out of Zambia, by this air-ambulance service provider, it was part of a staged 
evacuation originating out of the Democratic Republic of Congo where the malaria diagnosis 
was made.  
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Table 15: Initial clinical parameters of intubated patients. 
      
            
Reason for 
intubation GCS SBP HR RR SpO2 O2 Hgt 
Referring 
facility 
sp. 
Receiving 
facility 
sp. Country Season 
Decreased GCS 4 113 106 16 95% No 5.1 N/D P.f DRC Wet 
 
8 132 124 26 100% Yes 5.3 P.f P.f Nigeria Wet 
 
10 150 130 26 95% No 15.3 P.f P.f Mozambique Dry 
 
10 180 113 18 98% Yes 15.1 P.f + P.o P.f Nigeria Dry 
 
10 112 83 36 100% No 4.1 N/D P.f Mozambique Dry 
 
14 91 95 28 94% Yes 6.7 N/D P.f Congo Wet 
 
14 111 120 28 98% Yes 5.7 P.f N/D Nigeria Wet 
            GCS and 8 145 105 46 79% Yes 7 P.f P.m DRC Dry 
respiratory 9 139 117 47 84% No 4.1 N/D N/A Ghana Wet 
            Respiratory  15 140 122 30 61% Yes 4.6 N/D P.v Angola Wet 
            In situ N/A 77 128 14 93% Yes 8.2 N/D P.f DRC Wet 
 
N/A 151 110 16 99% Yes 4.2 P.f P.f Mozambique Dry 
 
N/A 101 88 12 100% Yes 6.3 N/D P.f Zambia (DRC) Dry 
 
N/A 118 75 14 100% Yes 6.4 N/D P.f Angola Wet 
 
N/A 135 125 12 94% Yes 5.6 P.f +P.o P.f Madagascar Wet 
 
 
 
3.9 Malaria treatment administered by the referring facility and during the air-ambulance             
flight. 
 
Forty-nine of the 82 patients were on intravenous quinine as part of the treatment regimen from 
the referring facility as shown in table 17. Seven of the 49 patients were changed to intravenous 
quinine by the referring facility after initially being on artemesinin derivatives which included oral 
artemether-lumefantrine (coartem®) in four patients, artemether as monotherapy without 
specification of administration route in one patient, oral artemether-lumefantrine combined with 
intramuscular artemether in one patient, and artemether with sulfadoxine-pyrimethamine 
(fansidar®) in one patient. 
 
Of the 49 patients, 24 patients were on intravenous quinine alone and 13 patients were on 
intravenous quinine in combination with an antibiotic. Four patients were on third generation 
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cephalosporins (ceftriazone, cefotaxime), one patient received a second generation 
cephalosporin (cefuroxime), two patients were receiving penicillin and beta-lactamase inhibitor 
combinations (amoxicillin/clavulanic acid), three patients received tetracyclines (doxycycline), 
two patients were administered quinolones (ciprofloxacin), and one patient was administered a 
nitroimidazole derivative (metronidazole).  
 
The flight crew administered the next due intravenous quinine dose to 19 of the 49 patients. 
Twenty-nine of the 49 patients were not due their next dose during flight, and in one case the 
crew elected not to give intravenous quinine as the flight crew disagreed with the initial 
diagnosis of malaria. In one case intravenous quinine had been changed to intravenous 
artesunate by the referring facility which was not due during the flight. A further seven patients 
received an initial loading dose of intravenous quinine from the flight crew, totalling 26 
intravenous quinine administrations during flight by the flight crew. 
 
Nine patients were not administered intravenous quinine by the referring facility or the flight 
crew. Four of these patients were on oral artemether-lumefantrine and two patients on 
intravenous artesunate. A patient, who had forgotten to take the 200mg oral artesunate as part 
of his sulfadoxine-pyrimethamine combination regimen took the tablets during flight. One patient 
from Malawi was on oral halofantrine (after initially being on artemether-lumefantrine) which was 
not due during the flight. Intramuscular artemether 80mg was administered by the flight crew in 
one patient as it was due during the flight. 
 
The flight crew differed with the referring facility diagnosis of suspected malaria in four cases 
and did not administer any anti-malarial treatment during the flight. In all four cases the 
diagnosis was confirmed not to be malaria. One patient flown out of Angola had already 
completed his sulfadoxine-pyrimethamine (fansidar®) course. Two patients flown from Zambia 
63 
 
and Angola respectively had no documentation regarding treatment administered at the 
referring facility. A patient who was flown out of Ghana had received a loading dose of 
intravenous quinine and had a follow-up negative malaria film at the referring facility. The 
diagnosis was confirmed as pneumonia at the receiving facility. 
 
Anti-malarial treatment was deferred in a further six patients, including an 18 week pregnant 
patient from Zambia, until a definitive diagnosis was made at the receiving facility. Three of the 
six patients had completed a course of artemether-lumefantrine, one had completed a 
sulfadoxine-pyrimethamine with artesunate course and the no documentation on the referring 
facility treatment was received in one patient from Angola. 
 
One patient from the Democratic Republic of Congo had developed a second degree heart 
block on intravenous quinine which was subsequently stopped by the referring facility and one 
patient from Mozambique refused intravenous quinine administration by the flight crew after 
having completed her artemether-lumefantrine course in Mozambique. 
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Table 16: Referring facility and flight crew anti-malarial treatment. 
     
        
Referring facility treatment regimens (n) 
IV 
quinine 
due 
(n)
 
IV 
quinine 
not 
due  
(n) 
IV 
quinine 
loading 
dose  
(n) 
Other 
anti-
malarials 
due  
(n) 
Other 
anti-
malarials 
not due 
(n) 
Not 
malaria 
(n) 
IV Quinine 24 13 11 
    IV Quinine and antibiotic 14 3 10 
   
1 
Other 
a 
then changed to IV quinine 7 2 5 
    Other b then changed to IV quinine and antibiotics 4 1 3 
    Other c and antibiotic 3 
  
3 
   Atovaquone-proguanil 1 
  
1 
   Crew unsure of treatment received 5 
  
3 
  
2 
Other 
d 
9 
   
3 6 
 Other e and antibiotic 5 
   
2 3 
 IV quinine then changed to IV artesunate 1 
    
1 
 IV quinine stopped due to side effects 1 
      Deferred treatment 6 
      Patient refused IV quinine after completing artemether-
lumefantrine course 1 
      Completed sulfadoxine-pyrimethamine  course 1 
     
1 
        a Artemether-lumifantrine, artemether, sulfadoxine-pyrimethamine 
      b Artemther-lumifantrine, sulhfadoxine-pyrimethamine, doxycycline 
      c Artemether-lumifantrine, artesunate, artemether 
       d Artemether-lumifantrine, artesunate IV, artesunate + sulfadoxine-pyrimethamine, IMI artemether, halofantrine 
  
e
 Arthemether-lumifantrine, artemether, quinine 
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CHAPTER 4: DISCUSSION  
 
 
4.1 Summary of results. 
 
This 3-year retrospective study reviewed flight documentation of 679 adult expatriates and long-
term travellers who were evacuated by fixed-wing air-ambulance from 30 of the 49 (excluding 
South Africa) sub-Saharan African countries to Johannesburg, South Africa. Suspected malaria 
cases were flown out of 14 sub-Saharan African countries, which included:  Angola; Cameroon; 
Congo; the Democratic Republic of Congo; Equatorial Guinea; Ghana; Madagascar; Malawi; 
Mozambique; Nigeria; Tanzania; Uganda; Zambia and Zimbabwe. Patients were mainly 
evacuated out of Eastern and Central Africa with the majority of flights originating out of Angola, 
Mozambique and the Democratic Republic of Congo. No suspected malaria cases were flown 
out of Lesotho, Mauritius, Réunion and Seychelles which are malaria-free. [53]  
 
Suspected malaria was the most common specific diagnosis at the time of air-ambulance 
dispatch when compared to the other clinical groupings of trauma, surgical, obstetric, cardiac 
and other medical diagnoses. The majority of suspected malaria patients were correctly 
diagnosed at the referring facility. RDTs were the most accurate diagnostic method and clinical 
signs alone were the least accurate. P. falciparum was the most commonly isolated species at 
both the referring and receiving facilities, however the majority of patients did not have specific 
species documented at both facilities. Malaria species isolated at the referring and receiving 
facilities were expected for the country of origin except for one case flown out of Angola. 
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No seasonal trend could be demonstrated as flights for suspected malaria occurred in similar 
numbers over the wet and dry seasons when reviewing the five countries most commonly flown 
to during the study period. Suspected malaria patients were predominantly male with a mean 
age of 42.1 years and travelling for business or occupational reasons. The majority of patients 
were South African Nationals. 
 
Malaria chemoprophylaxis was poorly utilised with only 2.4% of patients being compliant on 
appropriate chemoprohylaxis. One in five of the suspected malaria patients required intubation 
as a marker of disease severity. One patient died in-flight as a result of severe malaria. No 
specific malaria treatment regimen could be identified for a specific country. The majority of 
complicated malaria patients flown out of sub-Saharan Africa were still receiving intravenous 
quinine and not artesunate as treatment for complicated malaria. 
 
 
 
4.2 Limitations of the study. 
 
Records utilised for this review were from one air-ambulance provider (operating out of 
Johannesburg), which is contracted to specific corporate clients and medical/travel insurance 
companies. The fee-for-service operational policy of this air-ambulance provider will select for a 
specific study patient population and thus results are not reflective of the entire expatriate and 
long-term traveller population in sub-Saharan Africa. The profile of patients flown may thus be 
influenced by availability of financial backing rather than on clinical presentation of the disease 
alone. A further limitation of this study is that data from other air-ambulance providers operating 
out of South Africa have not been included in this review. This, combined with the relatively 
short period reviewed has resulted in a small sample size. 
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There is a paucity of data in the literature on expatriates being evacuated for suspected malaria 
from sub-Saharan African countries. This limits the ability to compare results of this study with 
previous studies. There was also no widely accepted definition in the literature as to what 
defines a long-term traveller. 
 
Data captured was dependent on the thoroughness of pre-flight, in-flight and post-flight 
documentation.  For several parameters, incomplete documentation may have resulted in 
skewed results due to small sub-groups for analysis. Limited documentation was most apparent 
regarding Plasmodium species isolation at the receiving facilities, with more than half of the 
patients having no documentation on species isolated. Therefore the size of this sub-group 
analysed was much smaller than expected. Nearly a quarter of patients had no documentation 
on the utilisation of chemoprophylaxis resulting in a small sub-group of patients who were 
documented to be compliant on chemoprophylaxis. 
The format and structure of the in-flight medical report form ensured the capturing of similar 
basic information as shown in appendix A. The quality of the post-flight medical report varied 
from case to case with regards to the extent of the information obtained and documented. The 
measure of the detail in the post-flight medical report is largely dependent on the medical 
assistance company’s client expectations. For certain clients a basic report confirming safe 
admission is expected whereas other clients may expect continuous daily medical monitoring 
with detailed updates to their in-house medical team. As the initial, and in some cases final post-
flight medical report is obtained within 1-2 hours post admission, the malaria film results may not 
be available at that time. This means that data captured from the post-flight medical report may 
be incomplete, especially with regards to malaria species identification.  
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Air-ambulance evacuations out of Africa may be challenging as language barriers may be 
encountered. In certain cases, handover may be taken either at the referring hospital or at the 
airport for security or flight-on-duty issues, without the presence of an English speaking health 
care worker. At times no medical records may be available for the flight crew to review.  As 
expatriates may not be fluent in English, this may present another hurdle in obtaining detailed, if 
any, information. The potential impact of these language barriers on the results of this review is 
difficult to gauge. Information regarding malaria chemoprophylaxis and treatment administered 
may have been lost in translation and thus skewed results. 
 
No data were available on the exact time of malaria diagnosis, the period of illness prior to the 
diagnosis or the timelines of when malaria treatment was started. This limited the ability to 
ascertain delays in help-seeking behaviour as a reason for the severity of illness upon 
presentation of the suspected malaria patients. 
 
 
 
4.3 Background. 
 
The medical assistance company associated with the air-ambulance service provider utilised in 
this study services the world's largest oil and gas, mining, and large-scale construction 
companies, as well as large military and civil departments, government institutions, embassies 
and non-governmental organizations. [41]  The company is based in Johannesburg and is the 
Africa branch of 27 alarm centres worldwide. [41] Due to geographical proximity, sub-Saharan 
African countries are expected to be the countries of origin for the majority of evacuations. 
Patients located geographically closer to Europe may be flown to South Africa instead of Europe 
due to visa restrictions (which pertain to pilots, flight crew and patients), as well as the limited 
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availability of European air-ambulance service providers. The medical assistance company will 
recommend the safest, fastest and most appropriate local referral or mode of transport based 
on the medical condition of the patient and the adequacy of the local medical infrastructure.  
 
 
 
4.4  Malaria in Africa.  
 
An estimated 212 million malaria infections occurred in the Africa region during 2006, with 106 
million of these cases presenting in Nigeria, the Democratic Republic of Congo, Ethiopia , 
Kenya and Tanzania. [18] Because of the high prevalence of the disease in sub-Saharan Africa, 
coupled with the fact that that the study patient population were expatriates (non-immune), it is 
not surprising that malaria was found to be the most common specific initial diagnosis affecting 
81 (11.9%) of the 679 patients flown.  
 
 
 
4.5 Diagnosis of malaria. 
 
Of the 82 initial and crew diagnosed suspected malaria patients, the diagnosis at the receiving 
facility was confirmed as malaria in 61 patients, and excluded in 12 patients. Several symptoms 
and signs of malaria are shared by other disease processes. It is thus not surprising that the 
diagnosis of malaria was incorrectly made in 12 cases. Nine patients had no documented 
confirmatory test results from the receiving facility. Of these nine patients, one patient did not 
have a documented initial method of malaria diagnosis and two patients were diagnosed on 
clinical symptoms alone. Due to the method of initial diagnosis these three cases were not 
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included in the final confirmed malaria group. One patient who was flown with a 4+ P. 
falciparum film died in-flight and was accepted as a confirmed malaria case due to the species 
identified and the documented hyper-parasitaemia. The remaining five patients had an initial 
diagnosis based on a positive blood film from the referring facility. Without documentation on the 
time of initiation and duration of treatment prior to the flight crew assessment, these five cases 
were accepted as confirmed malaria cases without receiving facility confirmation of the 
diagnosis. Thus of the 82 suspected malaria cases, 67 were confirmed. 
 
The method of diagnosis at the referring facility was mainly based on blood films and RDTs.  
Of interest is that a 92.3% of suspected malaria cases were confirmed to be malaria at the 
receiving facilities for initial diagnoses based on RDTs when compared to the 78.4% of patients 
diagnosed initially with blood films. This may have been due to a larger proportion of patients 
initially diagnosed with blood films not having the final diagnosis documented at the receiving 
facility when compared to patients initially diagnosed by RDTs. The higher accuracy with 
patients initially diagnosed by RDTs may also have been due to a smaller chance of human 
error in reading RDTs, which require little training to interpret results, rather than isolating 
parasites accurately through a microscope in remote areas. [13] Although RDTs have 
demonstrated decreased sensitivity with decreasing parasite densities, a positive result will 
exclude other pathologies presenting with similar signs and symptoms as malaria and thus 
expedite appropriate malaria treatment. [8][14] As a lay person can utilise a RDT, it decreases 
dependence on clinical diagnosis in remote areas where access to microscopy and/or the level 
of training of the microscopist may be limited. Users need to be informed of the RDT’s 
limitations as far as false negative results are concerned and should consider initiating 
treatment even in cases of a negative test result where there is a high clinical index of suspicion 
of malaria, especially if the patient’s condition deteriorates. [14]  
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The microscopy results at the receiving facility which showed no parasites (negative film) may 
have been due to completion of treatment and resolution of malaria parasites by the time of 
arrival at the receiving facility, or incorrect initial diagnosis at the referring facility. False negative 
microscopy results may also occur with parasite densities less than 5-10 parasites/µl, or with 
sequestration of P. falciparum parasites in the deep capillaries of the spleen, liver or bone 
marrow as well as in pregnant patients. [4][11]  P. falciparum sequestration may thus result in 
insufficient numbers of the parasite in the circulating blood leading to a negative blood film. [13]  
As parasite densities of P. malariae and P. ovale are often low, these mixed infections are often 
missed by microscopy, leading to false negative results. [11] Initial referring facility tests may also 
have been several days old by the time the air-ambulance provider was contacted for 
assistance, although without documentation delineating the timeframes of treatment initiation 
this could not be proven. In certain cases a dual pathology may have been present at the 
outset, with malaria resolution and only the second pathology present on arrival at the receiving 
facility as seen in one case flown out of Zambia. In this case the follow-up film was negative at 
the time of evacuation and the flight crew diagnosed atrial fibrillation complicated by congestive 
cardiac failure which was confirmed as the diagnosis at the receiving facility. 
 
 
 
4.6 Malaria species incidence. 
 
P. falciparum alone or in combination with other Plasmodium species was isolated in 15 (88.2%) 
of the 17 cases where the species was documented at the receiving facilities. This incidence is 
higher than the 40.6% -76.8% P. falciparum (alone or in combination) documented in other 
studies. [23][24] Although it can be assumed that the majority of complicated malaria cases will be 
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due to P. falciparum, it is unfortunate that no species identification was recorded in more than 
half of the suspected malaria patients at the receiving facilities.  
 
Cases of an initial RDT positive malaria diagnosis could not be included into the P. falciparum 
group unless specific mention was made of the species isolated in the test. Commercially 
available RDTs are available as two, three or four band tests and contain different combinations 
of target antigens isolating different species of malaria to suit local malaria epidemiology. [4][11] 
Information regarding the specific type of RDT used at the referring facility was not always 
available. Thus the initial referring facility isolation of P. falciparum may have been higher, 
however it cannot be assumed as a positive RDT may refer to a species other than P. 
falciparum or even a combination of Plasmodium species. 
 
P. falciparum was diagnosed in combination with P. ovale in two patients originating out of 
Nigeria and Madagascar respectively. The patient from Nigeria had a confirmatory film at the 
receiving hospital for both strains. Receiving facility species was not documented for the patient 
originating out of Madagascar. Both Nigeria and Madagascar have mosquitoes infected with P. 
ovale, which account for an estimated 5% of the Plasmodium infections in both Nigeria and 
Madagascar. [53] 
 
P. malariae in combination with P. falciparum was diagnosed in one patient originating out of 
Mozambique, without confirmatory species isolation documentation at the receiving hospital. P. 
malariae is a species that is known to be found in Mozambique and was thus not an unexpected 
finding. [53] 
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A patient originating out of Uganda had an initial diagnosis of blood film positive for P. 
falciparum, whereas the blood film at the receiving facility isolated a combination of P. ovale and 
P. vivax, both of which strains are found in Uganda. [53] 
 
Two patients flown out of Angola with an initial blood film diagnosis of P. falciparum malaria had 
different strains isolated at the receiving hospitals. In one patient P. malariae was also seen on 
the receiving facility film, which is unusual as it is not an expected species in Angola. [53] The 
latter patient had only travelled to the United States of America (without specifying the routing 
to/from the United States of America to Angola), and Angola in the preceding three months. As 
malaria is not found in the United States of America or any of its territories [30][53], this may mean 
that P. malariae has now spread to Angola, or that the patient had been infected during the 
routing to/from Angola. The second patient flown out of Angola had a film which was 
documented as ‘not otherwise specified mixed’ at the receiving facility. 
 
Thus, in all cases except the one case flown out of Angola, the species isolated initially and at 
the receiving facility were expected for the country of origin. 
 
 
 
4.7 Seasonal trends. 
 
Seasonal variation has to be compared to a specific country, as each sub-Saharan African 
country has unique geography and climate variations resulting in specific seasonal variances.  
The majority of suspected malaria flights originated out of the following five countries: 
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Angola 
Angola has two main seasons, the wet cooler months of November through April, and the dry 
warmer months of May through October.[54] Half of suspected malaria flights originating out of 
Angola were flown during the wet season, although cases were flown steadily throughout the 
year. A peak of 25% of all Angolan flights occurred during the month of June, which falls within 
Angola’s dry season. 
 
The Democratic Republic of Congo 
The Democratic Republic of Congo straddles the equator and has a rather unique seasonal 
distribution. The central region has an equatorial climate and a high annual rainfall of 1700mm 
annually. The northern and southern regions have reversed seasons, with the wet season in the 
north from April through October, and November through March in the south. [55]  The 
Democratic Republic of Congo has 3 distinct regions each with its own wet season, resulting in 
a wet region at any given time of the year. Thus unless specific areas are stipulated, the 
Democratic Republic of Congo as an entity has year-round wet seasons.   
All cases originating out of the Democratic Republic of Congo during this study period were 
flown out of either Kinshasa or Lubumbashi which are both situated in the south of the 
Democratic Republic of Congo. Although one patient was flown out of Zambia, the actual initial 
malaria diagnosis was made in the Democratic Republic of Congo and was thus included in the 
Democratic Republic of Congo group when looking at seasonal trends. Even though the 31.3% 
of the cases originating out of the Democratic Republic of Congo were flown during the southern 
region’s wet season (November through March), the actual peak was during April and May with 
43.8% of cases being flown during this period. The true origin and exact location of malaria 
infection within the Democratic Republic of Congo was not always documented, so certain 
malaria cases may have been infected in the north, or on the equator, and the south may have 
been purely the port of exit. 
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Mozambique 
The suspected malaria cases flown out of Mozambique were distributed throughout the year. 
Only 30.8% of the malaria flights originating out of Mozambique occurred during the country’s 
rainy season which starts in December through March. [56]  
 
Nigeria 
Nigeria has a tropical climate with the rainy season extending from April to October, with June 
being the wettest month. [57] The majority of flights fell within the wet season. However, the most 
number of flights in a single month occurred in November, which falls within the dry season. 
 
Zambia 
Zambia has three distinct seasons with December through April being warm, wet and humid, 
May through August is cool and dry and September through November is hot and dry. [56] All of 
the suspected malaria evacuations originating out of Zambia occurred within the wet, humid 
season. 
 
Of interest is that there was a peak in flights for both Nigeria and the Democratic Republic of 
Congo in the dry month immediately following the last wet month of each respective country. 
These peaks are in keeping with the findings of the WHO, who found the risk of malaria 
infection was found to be the highest at the end of the rainy season or soon thereafter. [52] 
These peaks may be due to P. falciparum’s incubation period which ranges from 7 to 30 days, 
resulting in cases that may have been infected during the end of the wet season to present in 
the following month which falls within the dry season. [2]  
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No seasonal variation was shown when reviewing all suspected malaria flights, with near equal 
numbers of patients flown during the wet and dry seasons. The importance of this may be that 
travellers and expatriates should be advised to utilise malaria chemoprophylaxis throughout the 
year. Suspected malaria cases were flown throughout the year from all countries except for 
Zambia where all flights occurred during the wet season.  
 
 
 
4.8 Suspected malaria patient demographics. 
 
Expatriates and long-term travellers with a diagnosis of suspected malaria in this study showed 
a predominantly male distribution of 84.1%. This is in keeping with the 62.9-64.8% male majority 
found in previous studies of European travellers returning from Africa with imported malaria. 
[25][32] Of the cases where the reason for travel was documented, 65 (98.5%) of the 66 
suspected malaria patients were in sub-Saharan Africa for business/occupational reasons. 
Leisure was the purpose for travel in only one suspected malaria patient - a female, flown out of 
Ghana. Business/occupation as the reason for travel ranged from 23.2% - 29.8% in studies of 
American and European travellers returning home with imported malaria. [25][27]The 
predominantly male gender discrepancy as well as business/occupation as the main reason for 
travel, was most likely due to the spectrum of clients serviced by the medical assistance 
company. These clients are often based on remote sites, mines, military postings and offshore 
oil installations in sub-Saharan Africa and one would thus expect the majority of staff to be male. 
The mean age of the suspected malaria patients was 42.1 (range 18-68 years), which is in 
keeping with the mean age of 35.8 (range 1-86 years) to 44.1 years documented in other 
studies of European and American travellers returning from Africa with imported malaria. [25][37]  
 
77 
 
When considering the respective nationalities of the patients flown, it was found that the majority 
were South African citizens. The reason for this might be that companies seeking skilled labour 
may source such labour from countries in close geographical proximity to the area of need so as 
to curtail travel expenditure when employees move between their home country and place of 
work. 
 
 
 
4.9 Malaria chemoprophylaxis. 
 
Malaria chemoprophylaxis whilst working and travelling in malaria-endemic areas was utilised in 
11 (13.4%) of suspected malaria patients with only two of these 11 patients confirming 
compliance. Thus, only two (2.4%) of all 82 suspected malaria patients were compliant on 
chemoprophylaxis. As 20 (24.4%) of the suspected malaria cases did not have malaria 
chemoprophylaxis documented the results could be skewed. The rate of chemoprophylaxis 
utilisation found in this study  was lower than several studies which showed chemoprophylaxis 
utilisation rates ranging from  19.0 - 83%, and chemoprophylaxis compliance rates on 
appropriate regimens ranging from 5.7 – 97.1%. [25][27][32][35][37] The higher figures in compliance 
rates were found in studies where travellers visited travel clinics. These travellers may have 
received appropriate detailed pre-travel advice resulting in an increased awareness of the risks 
associated with malaria and have been more willing to take precautions to prevent malaria.  
 
All patients, save one, were on appropriate chemoprophylaxis for the country of evacuation 
origin. The aforementioned patient was flown out of Angola and had utilised chloroquine 
inappropriately, as all sub-Saharan countries except Western Sahara, have shown chloroquine 
resistance as shown in figure 15. [53][58] Mefloquine was the most popular chemoprophylaxis 
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choice, followed by doxycycline and atovaquone-proguanil.  These three pharmacological 
agents offer protection from all four malaria species and are recommended types of 
chemoprophylaxis for the 14 sub-Saharan African countries of evacuation origin for the 
suspected malaria patients. [53] 
 
The fact that two patients were known to become infected with malaria whilst being compliant 
on appropriate chemoprophylaxis highlights that no chemoprophylactic regimen offers complete 
protection. At most chemoprophylactic regimens offer 75-95% protection from malaria infection 
even when taken correctly. [35][52] Patients may stop taking chemoprophylaxis or change their 
anti-malarial agent based on adverse effects, a perceived low risk of malaria or on the advice of 
medical staff or local colleagues. [35] Of the two patients who defaulted chemoprophylaxis, one 
patient stopped taking his chloroquine due to gastro-intestinal side-effects and dry hands, 
whereas the second patient stopped taking his mefloquine due to the side effects of sleepiness 
and morning nausea. 
 
Offshore oil-rigs may advise their employees that no chemoprophylaxis is required whilst off-
shore, due to the distance from the mainland, resulting in a higher risk of forgetting to take 
chemoprophylaxis prior to disembarkation to the mainland after the tour of duty ends (personal 
communication with oil rig doctor, offshore Nigeria – 2010 August). Certain remote site 
companies do not have a malaria chemoprophylaxis policy in place and prefer to rather treat 
malaria early than prevent it (personal communication with mine site doctor, the Democratic 
Republic of Congo – 2011 February). 
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Figure 15: Malaria-endemic countries in the Eastern Hemisphere. 
Utilised with kind permission from the Centres for Diseases Control, and available from: 
URL:http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/malaria.aspx#989 
 
 
 
4.10 Counterfeit and sub-standard anti-malarials. 
 
Long-term travellers and expatriates are more likely to purchase their anti-malarials in the sub-
Saharan country of temporary residence due to their prolonged period of stay in that country. 
Anti-malarials obtained in Nigeria and tested in one study showed that 37% of the anti-malarials 
tested lacked active ingredient or contained sub-optimal quantities of the active ingredients. [43] 
78% of the drugs tested were obtained from private Nigerian institutions. The potential dangers 
of ineffective anti-malarial agents is self-evident. The fact that the majority of these sub-standard 
drugs were purchased from private institutions is even more disconcerting. Thus patients may 
receive treatment for uncomplicated malaria from a private institution and unwittingly receive 
sub-standard drugs, increasing their risk of progressing to complicated malaria as potentially no 
80 
 
active ingredient is being administered. A patient may be compliant on an appropriate 
chemoprophylaxis regimen, procured locally in sub-Saharan Africa, whilst sub-optimal or even 
no active ingredient may be present in the chemoprophylaxis. [35][43] This may result in travellers 
not identifying malaria symptoms for what they are at an early stage, as malaria infection is not 
suspected due to a false sense of protection. 
 
Utilisation of sub-standard drugs may result in malaria resistance to the specific agent as sub-
therapeutic levels are administered, selectively killing susceptible parasites whilst leaving 
resistant parasites to flourish. [44] Counterfeit anti-malarials with too much active ingredient may 
precipitate toxic or adverse effects resulting in discontinuation of malaria prophylaxis or 
treatment with dire consequences. Education of travellers by travel clinics, physicians and 
companies deploying employees to malaria-endemic countries on the dangers associated with 
purchasing medication in sub-Saharan Africa, excluding South Africa, is the key to avoid using 
counterfeit and sub-standard anti-malarials. Travellers should ensure adequate stock of anti-
malarials are procured from a reliable source for the duration of their stay. Alternatively they 
would need to arrange a shipment of anti-malarials, or return to their home country frequently to 
procure further stock. [35] 
 
An additional aggravating situation is that access to anti-malarial treatment is limited. It is 
estimated that in 18 of the 46 WHO African-region countries, access to anti-malarials was on 
average only 38%. [18] Suspected malaria flights originated out of six of these 18 countries 
including: Angola; Cameroon; Ghana; Malawi; Uganda and Zambia. 
 
So in summary, there is limited access to anti-malarial drugs (both prophylactic and therapeutic) 
which are often of questionable efficacy.  
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4.11 Clinical presentations. 
 
Suspected malaria patients in this study presented with a wide range of organ systems affected 
including central nervous system, haematological, renal, endocrine, respiratory and 
cardiovascular systems. An interesting finding was the incidence of patients (19.5%) displaying 
cerebral compromise suggesting and advanced disease process at the time of assessment by 
the flight crew. 
Although a quarter of patients with documented Hb levels had a Hb of less than 10 g/dL only 
three patients received RPC transfusions. This may have been due to patients being clinically 
stable despite the low Hb level. The importance of the ability of the air-ambulance service 
provider to obtain and transport appropriate emergency blood products is emphasised with 
patients presenting with Hb levels as low as 4.4 g/dL.  
 
In a review by Dondorp et al. it was found that anaemia in severe malaria resulted from a 
combination of parasitized RBC destruction at schizont rupture, ineffective erythropoiesis as 
well as accelerated removal of RBC (both parasitized and un-parasitized).[59] In severe P. 
falciparum, red cells have reduced deformability which may cause microcirculatory flow 
obstruction and are prone to being filtered out by the spleen, contributing to anaemia in malaria.  
[59]   
 
Macroscopic haemoglobinuria as a sign of intravascular haemolysis was documented in 15.9% 
of the 82 patients. None of the aforementioned patients had blackwater fever, defined as 
severe, acute intravascular haemolysis with haemoglobinuria and a dramatic fall in Hb value.[60] 
A study by Bruneel et al. documented the characteristics of 21 European patients who 
presented with blackwater fever in France between 1990 and 1999 after living in sub-Saharan 
Africa. [60] The duration of residence in Africa ranged from 4 to 37 years with a mean of 18.1 
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±8.9 years. The country of residence was the Central African Republic, Ivory Coast, Cameroon 
Guinea, Gabon, Congo, Burkina Faso, Benin and Togo. None of the 21 patients had utilised 
malaria chemoprophylaxis. All 21 patients presented with macroscopic haemoglobinuria, 
fatigue, jaundice and a slate-grey skin colour. The Hb level ranged from 3.0 to 9.0 g/dL with a 
mean of 5.3 ± 1.5 g/dL. [60]  
 
Less than 10% of the suspected malaria patients had demonstrable pyrexia of more than 
38.4ºC, which may be due to the fluctuations in pyrexia typically found in malaria. Administration 
of antipyretic agents such as paracetamol could also have resulted in fewer patients having 
increased temperature measurements. The fever found in malaria is due to merozoites being 
released from the red blood cells during the erythrocytic cycle of malaria -triggering an immune 
response. [1][3] 
 
Both patients who were found to have hypoglycaemia with blood glucose levels of 2.4 mmol/L 
and 2.9 mmol/L respectively, had received intravenous quinine at the referring facility and were 
not on glucose containing fluids at the time of assessment. The former patient received the next 
due dose of intravenous quinine in a glucose containing fluid and remained persistently 
hypoglycaemic during the flight necessitating repeated intravenous dextrose administration. 
This case emphasises the need for continual blood glucose monitoring in patients receiving 
quinine, even when quinine is administered in a glucose containing fluid. 
 
Clinical jaundice was documented in a third of the suspected malaria patients. 20% of the 
clinically jaundiced patients presented with concurrent macroscopic haemoglobinuria. Jaundice 
in malaria may be due to pre-hepatic haemolysis or due to hepatitis from the opportunistic 
infections leading to sepsis.  
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4.12 Intubation as a marker of severity. 
 
Intubation was used as a marker of severity of illness. The need for intubation may be to afford 
airway protection or to facilitate ventilation. The loss of the ability to protect the airway indicates 
decreased cerebral function, whereas the need for intubation for mechanical ventilation 
indicates decreased pulmonary function. Intubation and ventilation may also be required for 
other conditions such as metabolic derangements. Intubation was required in 18.3% of the 82 
suspected malaria cases. 10 of the 15 patients were intubated by the flight crew, seven for a 
depressed level of consciousness and two for a combination of respiratory failure and 
depressed level of consciousness and one for respiratory failure. Five of the patients were 
already intubated at the time of assessment by the flight crew without clear documentation of 
the reason(s) for intubation.  
 
The severity of illness on presentation could be attributed to several factors, although it should 
be noted that no flight crew documentation was available to substantiate the following: 
i) Delayed help-seeking behaviour which may be due to a lack of education on malaria 
prior to travel leading to the inability to recognise early malaria symptoms [27], a fear 
of job loss due to absenteeism, the limited availability/ accessibility to healthcare in 
remote areas in sub-Saharan Africa or even cultural beliefs with self-treatment 
initially with traditional/herbal remedies.  
ii) A delay in initial accurate diagnosis which may be due to limited or no medical 
facilities, the lack of RDTs or access to reliable microscopy. Initial false negative 
RDTs which may be due to insufficient parasites to register a positive result as non-
immune patients present with clinical symptoms at lower parasite densities. RDT 
cassette damage may reduce the sensitivity. A false negative RDT result may also 
occur when the RDT utilised fails to detect the Plasmodium species causing the 
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illness. Initial false negative microscopy may be due to parasite densities less than 5-
10 parasites/µl, or with sequestered P. falciparum parasites which may result in 
insufficient numbers of the parasite in the circulating blood. [4][11][13] As parasite 
densities of P. malariae and P. ovale are often low, these mixed infections are often 
missed by microscopy. [11]  Malaria could present with flu-like symptoms resulting in 
initial self-treatment with flu remedies. 
iii) A delay in initiation of appropriate malaria treatment may be due to inadequate 
medication supplied to remote sites or clinics or an incorrect initial diagnosis. 
iv) Failed treatment may be due to inadequate exposure to the active anti-malarial 
ingredient (under-dosing of standard medication, vomiting, sub-optimal active 
ingredients in counterfeit medication), not utilising recommended combination 
therapies, poor adherence or drug resistance. [61] In one case a patient forgot to take 
the oral artesunate as part of his sulfadoxine-pyrimethamine combination regimen. 
Patients, unless specifically instructed to do so, may first complete one blister pack 
prior to starting on the next instead of taking the two tablets in combination. 
v) Patients may have underlying co-morbid conditions resulting in diminished baseline 
physiological reserve. 
vi) Patients may be pregnant which makes any infection of malaria complicated by 
definition.  
vii) Admission to hospital may result in noscocomial infections and/or complications from 
treatment administered e.g. hypoglycaemia and dysrhythmias from intravenous 
quinine. 
 
No statistically significant difference (p=0.50) was shown for intubation requirements when 
comparing patients who had utilised malaria chemoprophylaxis with the patients who had not, 
nor when comparing intubation requirements of patients who had utilised chemoprophylaxis with 
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patients where chemoprophylaxis utilisation was not documented (p=0.39). It should be noted 
that the sub-groups utilised for analysis were small. 
 
None of the patients in this study were deemed unfit to fly due to the severity of the condition 
after the assessment by the flight crew. The initial assessment by the flight crew of the patient 
who died in-flight was that the patient was fit to fly and stable for transport. Crew may under 
exceptional circumstances request to stand down an air-ambulance flight post patient 
assessment. These rare cases are escalated to the air-ambulance service provider’s medical 
director who will make the decision on whether to proceed with the mission or not after weighing 
up all available information. The case-fatality rate in this study was 1.2% which is higher than 
the 0.6-0.9% mortality rates documented  in other studies. [25][27] It should be noted that the 
mortality rate in this study only includes the single death in-flight and may have been even 
higher as this study did not follow-up patients to the time of discharge from the receiving 
facilities. 
 
 
 
4.13 Malaria treatment administered at the referring facility and during the air-ambulance             
flight. 
 
The majority (59.8%) of suspected malaria patients were on intravenous quinine as part of the 
treatment regimen from the referring facility, with half of these patients also on an antibiotic. The 
flight crew administered intravenous quinine to 26 patients during the flight with seven of these 
patients receiving the initial loading dose from the flight crew and the remainder (19 patients) 
requiring the next due dose during the evacuation mission. The balance of the patients already 
receiving quinine were not due the next dose for the duration of the mission. 
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A treatment regime of an anti-malarial (oral, intravenous or intramuscular) in combination with 
an antibiotic was initiated by the referring facility in 31.7% of patients. The choice of antibiotics 
included third generation cephalosporins (ceftriazone, cefotaxime), second generation 
cephalosporins (cefuroxime), penicillins (amoxicillin), penicillin and beta-lactamase inhibitor 
combinations (amoxicillin/clavulanic acid), tetracyclines (doxycycline), quinolones 
(ciprofloxacin), and nitroimidazole derivatives (metronidazole).  
The WHO recommends doxycycline or clindamycin as part of the second line treatment 
regimens when used in combination with either artesunate or quinine. [61]  The WHO also 
recommends a third generation cephalosporin with gram-negative and gram-positive cover, or 
an antibiotic with proven efficacy against the causative pathogen in opportunistic infections in 
malaria. [61] One patient who had received ciprofloxacin for a urinary tract infection was the only 
patient with a documented reason for antibiotic choice. The reason(s) for specific antibiotic 
selection(s) and the reasoning behind antibiotic initiation was not documented in the remaining 
cases and thus appropriateness could not be assessed. 
 
Oral antimalarial regimens included artemesinin derivatives (artemether-lumefantrine, 
artemether, artesunate), sulfadoxine-pyrimethamine , atovaquone-proguanil, halofantrine, oral 
quinine and artemether combined with sulfadoxine-pyrimethamine. Intravenous treatment 
regimens included quinine or artesunate. Artemether was the only treatment regimen 
administered intramuscularly. 
 
No specific correlation was shown with the choice of anti-malarial treatment regimens to the 
countries where evacuations originated from. Artemether-lumefantrine was administered as a 
sole anti-malarial agent or in combination with other antimalarials and/or antibiotics in a quarter 
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of the 82 suspected malaria patients. These patients were flown from Nigeria, Mozambique, 
Malawi, Angola, the Democratic Republic of Congo, Zambia, Madagascar and Ghana.  
 
Sulfadoxine-pyrimethamine in combination with an artemesinin based derivative was 
administered to patients flown from Nigeria, Mozambique and Zambia. Sulfadoxine-
pyrimethamine was administered to patients flown from Zimbabwe and Angola. Artesunate was 
administered to patients originating from Tanzania, Equatorial Guinea and Mozambique. 
Artemether as mono-therapy was administered to patients originating from Angola, Ghana, 
Mozambique and Uganda. Halofantrine in combination with artemether-lumefantrine, oral 
quinine and  atovaquone-proguanil were administered to patients originating from Malawi, the 
Democratic Republic of Congo and Angola. It should be noted that in certain cases the patients 
had completed the anti-malarial course and/or had been initiated on intravenous quinine for 
severe malaria at the time of flight crew assessment. 
 
In two cases the patients had received a combination of medications without documentation as 
to when and why medications were initiated and/or discontinued by the referring facility. One 
patient from Zambia had received artemether-lumefantrine, doxycycline, sulfadoxine-
pyrimethamine, ciprofloxacin and cefotaxime. The second patient from Ghana had received 
artemether, ciprofloxacin, cefuroxime and amoxicillin/clavulanic acid. Injudicious administration 
of medication may lead to drug reactions and interactions. [61] 
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CHAPTER 5: CONCLUSIONS 
 
This retrospective analysis has yielded some interesting results. Suspected malaria was the 
single most common diagnosis for dispatching air-ambulances during the review period. 
Patients in this study presented in advanced stages of severe/complicated malaria with 18.3% 
of patients requiring intubation as a marker of severity and one patient dying in-flight. These 
findings would suggest that malaria poses a material danger to expatriates and long-term 
travellers in sub-Saharan Africa.  
 
Despite the dangers of malaria, the utilisation of malaria chemoprophylaxis by the study 
population in this review was alarmingly low with only 2.4% of suspected malaria cases 
confirming compliance. However,  this review also found that the utilisation of malaria  
chemoprophylaxis did not decrease the severity of presentation (based on intubation 
requirements) and did not guarantee complete malaria protection. No statistically significant 
difference could be found in intubation requirements when compared to chemoprophylaxis 
utilisation, although it should be noted that the sub-group for this analysis was very small. 
 
This review emphasises the important role that RDTs have in detection of malaria in remote 
sites. 92.3% of cases diagnosed initially by RDTs were confirmed to be malaria at the receiving 
facility. Notwithstanding, the limitations of the RDTs should be borne in mind. False negative 
results due to low parasite loads or the inability of certain RDTs to detect the species of 
Plasmodium causing the illness could lead to malaria going untreated. 
 
Another interesting finding of the review was the incongruity of treatment regimens for malaria in 
various countries particularly regarding the addition of antibiotic second-line regimens. These 
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finding would suggest that the WHO protocols for treatment of malaria and not widely being 
adhered to. 
 
 
 
5.1 Recommendations for future work. 
 
Future studies should review the effect of flight crew management for suspected malaria cases 
during flights and whether outcomes improve. Additional parameters documented should 
include clinical features (prostration, convulsions, abnormal bleeding), biochemical features 
(acidosis, hepatic impairment, hypoxia) as well as haematological features (parasitaemia level, 
platelet level) as these are additional indicators of severe malaria. [61] These studies should also 
review the long-term outcomes of the patients who were evacuated, as this will provide a more 
accurate mortality figure. 
 
A study reviewing all the malaria cases monitored by the medical assistance company 
(associated with the air-ambulance service provider utilised in this study) will provide more 
accurate figures of malaria infections in expatriates in sub-Saharan Africa – whether evacuated 
or not. It will also be of interest to compare the number of expatriates requiring evacuation 
compared to the total number of monitored expatriate patients. 
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APPENDIX A: Example of the in-flight medical report form utilised by flight crew. 
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APPENDIX B: University of the Witwatersrand Human Research Ethics Committee  
  (Medical) clearance certificate. 
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APPENDIX C: Air-ambulance provider access to database authorisation letter. 
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